Dr. June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine and is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. The CAR T cells invented in the June laboratory were awarded “Breakthrough Therapy” status by the FDA for acute leukemia in children and adults in 2014 and were approved by the FDA for acute leukemia in 2017 and afterwards, for diffuse large B cell lymphoma. These accomplishments have been recognized by the White House on several occasions. He has published more than 500 manuscripts and is the recipient of numerous honors, including election to the National Academy of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society.

Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. (Biology) from Penn and a Ph.D. in Immunology and Infectious Diseases from Johns Hopkins. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,300 patients in clinical trials since 1996. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Dr. Levine is co-inventor on 28 issued US patents and co-author of >180 manuscripts and book chapters with a Google Scholar citation h-index of 89. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. Dr. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. Coulter Award for Healthcare Innovation, the National Marrow Donor Program/Be The Match ONE Forum 2020 Dennis Confer Innovate Award, serves as President of the International Society for Cell and Gene Therapy, and serves on the Board of Directors of the Alliance for Regenerative Medicine. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets.

Stephan Grupp, MD PhD, is Chief of the Cellular Therapy and Transplant Section, Director of the Susan and Steven Kelly Center for Cancer Immunotherapy, and Medical Director of the Cell and Gene Therapy Lab at CHOP, as well as Novotny Professor of Pediatrics (with tenure) at U Penn’s Perelman School of Medicine. He has authored over 250 articles and book chapters during his research career across the translational spectrum. He leads the largest pediatric cell therapy program in the country, a group which recently celebrated treating their 500th CAR T patient.Dr. Grupp came to CHOP in 1996 after receiving his MD/PhD in Cincinnati and doing his clinical training in Boston. His primary area of research is the use of CAR T and other engineered cell therapies in pediatric cancers and other life-threatening disorders such as sickle cell disease. He led all of the pediatric ALL trials of the CAR T product CTL019 (tisa-cel), including Novartis’ international registration trial, leading to the first FDA approval of a CAR product (Kymriah). As a result of this work, he presented the Clinical Perspective at the first FDA ODAC CAR meeting. He is currently the Study Steering Committee Lead for the Vertex international registration trial of their CRISPR-edited product for sickle cell disease. Dr. Grupp was elected to the National Academy of Medicine in 2019.

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development and is an author or co-author of over 100 publications. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016. Over the past several years he has been integrally involved in the response to various public health emergencies, and in 2022 he was elected a member of the National Academy of Medicine.

Georg Schett is Professor of Internal Medicine and since 2006 head of the Department of Medicine 3 - Rheumatology and Immunology at Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg in Germany.
Professor Schett graduated from the University of Innsbruck (Austria) in 1994. After his dissertation from medical school, he worked as scientist at the Institute of BioMedical Aging Research of the Austrian Academy of Science in Innsbruck. Two years later, he joined the Department of Medicine at the University of Vienna, where he completed his postgraduate training in Internal Medicine and subsequently in Rheumatology. In 2003 he was promoted to professor of Internal Medicine. Before accepting his position as the chair of the Department of Internal Medicine 3 in Erlangen, he worked as a scientist in the United States of America for one year.
Georg Schett’s scientific work includes a broad spectrum of clinical and immunological issues, particularly the molecular basics of immune-inflammatory diseases. Initially, he investigated the immunology of atherosclerosis and focused on antibody-mediated endothelial cell damage. His research work led to the understanding of the phenomenon of LE-cells in 2007. He was awarded the renowned START Award in 2002 and established a research group for arthritis in Vienna. In 2008, he initiated in collaboration with colleagues the priority program IMMUNOBONE in Germany, funded by the German Research Foundation (DFG). IMMUNOBONE aims to elucidate the interactions between the skeletal and the immune systems. Since 2015, Prof. Schett has led the DFG collaborative research centre 1181 “Checkpoints for Resolution of Inflammation” in Erlangen. Additionally, he is spokesperson of the project METARTHROS, funded by the Federal Ministry of Education and Research, which investigates the impact of the metabolism on arthritis. In 2019, he received funding for the ERC-Synergy grant “4D+ nanoSCOPE Advancing osteoporosis medicine by observing bone microstructure and remodelling using a four-dimensional nanoscope” of which he is spokesperson. 4D nanoSCOPE aims to develop tools and techniques to permit time-resolved imaging and characterization of bone in three spatial dimensions (both in vitro and in vivo), thereby permitting monitoring of bone remodelling and revolutionizing the understanding of bone morphology and its function. In 2021, Prof. Schett was appointed Vice President for Research at the Friedrich Alexander University of Erlangen-Nuremberg and became a Leopoldina member of the German National Academy of Sciences.
Professor Schett’s scientific work has been honored with several awards, including the Carol-Nachman Prize from Wiesbaden. In March 2023, Prof. Schett received the 2023 “Funding Prize in the Gottfried Wilhelm Leibniz Programme” awarded by the DFG. He has published over 1000 peer-reviewed papers.

Dr. Ho is a Senior Investigator, the Deputy Chief of the Laboratory of Molecular Biology, the Head of the Antibody Therapy Section, and the Director of the Antibody Engineering Program at the National Cancer Institute (NCI), National Institutes of Health (NIH). He received his Ph.D. from the University of Illinois at Urbana-Champaign, where he generated anti-idiotypic antibodies as cocaine antagonists. He completed a postdoctoral fellowship at the NIH, where he engineered immunotoxins targeting CD22 and mesothelin for the treatment of B cell leukemias and mesothelioma. Dr. Ho has pioneered the generation of therapeutic antibodies that target cancer-associated heparan sulfate proteoglycans. A focus of his laboratory work is on the validation of cell surface glypicans such as GPC3, GPC2 and GPC1 as new therapeutic targets in cancer. This area of research ranges from investigation of the fundamental mechanisms by which glypicans regulate Wnt, Yap and other signaling molecules to the design of antibody-based cancer therapeutics. His laboratory also established mammalian cell surface display, developed rabbit monoclonal antibodies, and built shark and camel single domain antibody phage libraries as new tools to advance antibody engineering and drug discovery. The immune therapeutics such as CAR-T cells based on his research are being tested at clinical stages for treating liver cancer, neuroblastoma, mesothelioma and other cancers.
Dr. Ho is was elected to the Board of Directors for the Antibody Society and to the Board of Directors for the Foundation for Advanced Education in the Sciences (FAES). Dr. Ho received many awards including the Asian & Pacific Islander American Organization (APAO) Scientific Achievement Award, Dr. Francisco S. Sy Award for Excellence in Mentorship at HHS, NIH Deputy Director for Intramural Research (DDIR) Innovation Award, and NCI Director’s Innovation Award.

Dr. Xiong is Professor (with tenure) at the Peking University and Nanchang University, China. His research interests focus on understanding the molecular and cellular mechanisms of heart regeneration and translational studies on heart disease. His lab contributes to discovering a small-molecule cocktail 5SM that promotes heart regeneration, determining the genetic interval of zebrafish cloche mutant, and establishing methods for generating CRISPR-induced zebrafish and rat mutants. He has published over 80 peer-reviewed papers including journals Nature Communications, Cell Research, Circulation Research, Cell Stem Cell, Development, etc. He held USA NIH K01 Award, and currently serves as advisory committee member of Chinese National Key R&D Program on Developmental Reprogramming and Metabolic Regulation, Vice Editor-in-Chief of the journal Cell Regeneration, and co-organizer for the “International Society for Regenerative Biology Webinars” and the biennial “Chinese Conferences on Organ Regeneration”.

Dr. Kaufman is a native of Minnesota (USA). He did undergraduate work at Stanford University and then completed an MD and PhD (Immunology) at the Mayo Medical School and Mayo Graduate School in Rochester, MN. He then completed both residency training in Internal Medicine and fellowship training in Hematology at the University of Wisconsin-Madison. Dr. Kaufman was faculty at University of Minnesota from 2002- 2016. In 2016, Dr. Kaufman moved to UCSD to be a Professor in Department of Medicine, Division of Regenerative Medicine and Director of the Cell Therapy program.
Dr. Kaufman provides clinical care primarily for patients with blood cell cancers such as leukemia, lymphoma and myeloma, with special interest in blood and marrow transplantation (BMT) and cell-based immunotherapies. Research in the Kaufman lab uses human pluripotent stem cells to understand the development of blood cells and related mesodermal cell populations. Specific projects investigate development of distinct cell populations from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), including: hematopoietic stem/progenitor cells, lymphocytes, endothelial cells, cardio-vascular progenitor cells, and osteogenic (bone forming) cells. Recent studies have focused on the ability to use hESC and iPSC-derived natural killer (NK) cells to kill diverse types of human cancer cells both in vitro and in vivo. Additional work has used cellular engineering to enhance the anti-tumor activity of the hESC/iPSC-derived NK cells by expression of novel chimeric antigen receptors, stabilized expression of CD16, and other strategies. This work has now been translated into clinical trials for treatment of relapsed/refractory cancers- both hematologic malignancies and solid tumors. Dr. Kaufman also oversees the UCSD Advanced Cell Therapy Laboratory (ACTL) that provides GMP cell manufacturing to translate new anti-cancer cell-based therapies to clinic, such as NK cells, T cell-based therapies, MSCs, and other hESC/iPSC-derived cell populations.

A medical doctor by training, Dr. Matter received his medical degree from the University of Basel and did immunology and pathology research in Switzerland, Britain, France and the United States of America before entering into the pharmaceutical industry. He has published more than 100 scientific articles plus several book chapters in the area of oncology and hematology. He is the recipient of the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award. He also was Associate Professor at the Medical School of the University of Basel for several decades and held fellowships at the Swiss National Science Foundation and the Swiss Academy for Medical Sciences.
Dr. Alex Matter is best known for his contribution to the development of Glivec/Gleevec, one of the world’s first tyrosine kinase inhibitor drugs against chronic myeloid leukemia (CML). Starting in the mid-eighties, Dr. Matter led a team of close to 200 scientists at Novartis to discover and optimize the lead compound and brought it all the way through its first clinical trial in 1998. In a short span of 3 years, Glivec/Gleevec was given a very rare, fast track FDA approval in 2001.
Dr. Matter was the founding director for the Novartis Institute for Tropical Diseases in 2003. Under his leadership, NITD successfully implemented research programs in the areas of dengue fever, tuberculosis and malaria attracting major grants from the Bill&Melinda Gates Foundation and the Wellcome Trust. NITD also joined the Singapore Dengue consortium and the Global Alliance for TB Drug Development. Dr. Matter has had a long association with A*STAR during his time in Singapore. He is a member of the Scientific Advisory Board of the Institute of Molecular and Cell Biology (IMCB) since 2005, a member of the A*STAR Investigatorship Selection Panel in 2007, and was a member of the Experimental Therapeutics Centre Project Review Committee in 2008.
Before coming to Singapore, Dr. Matter has held several positions of leadership such as Head of Cancer research at Hoffman-LaRoche, Head of Cancer and Virology Research at CIBA-GEIGY and more recently Global Head of Oncology Research, at Novartis Pharmaceuticals Corporation till 2003. Besides Glivec, his distinguished career with Novartis also includes heading drug discovery programs for anti-infectives and AIDS/HIV.
Dr Matter also co-founded the Esperanza Medicines Foundation, a non-profit organization that aims to develop affordable drugs for treatment and prevention of AIDS in developing countries.

Dr. Travis Young is the Vice President of Biologics at Calibr, a division of Scripps Research, where he was a member of Calibr’s founding principal investigators. He currently serves as the lead investigator on multiple bench-to-bedside antibody and cellular therapy-based programs. Dr. Young maintains a research group focused in the development of novel therapeutics at the interface between protein engineering and synthetic biology. This research spans multiple disease indications including cancer, autoimmune, metabolic disorders, and infectious disease. His work has been highly awarded and received support from the Wellcome Trust, NIH (National Cancer Institute), Department of Defense, Mesothelioma Research foundation, American Cancer Society, among others, in addition to receiving backing from major pharma groups which supports clinical translation of programs. His work has resulted in numerous publications and patents with ~2000 citations in the past 5 years. He received a BS in biochemistry from Boston College and a PhD in chemical biology from The Scripps Research Institute as an ARCS scholar. At Scripps, his work was foundational for the development of programs in the Calibr pipeline today, including a bispecific antibody for prostate cancer which will enter clinical trials next year. After receiving his PhD, he completed a postdoc at Harvard Medical School with an NIH fellowship, in the department of Biological Chemistry and Molecular Pharmacology.

Dr. Wang was trained by Dr. Adolfo García-Sastre and received her Ph.D. in Biomedical Sciences from the Mount Sinai School of Medicine in NYC. She joined Dr. Peter Cresswell’s laboratory in the Department of Immunology at Yale University as a Howard Hughes Medical Institute fellow, and later as a Cancer Research Institute postdoctoral associate. Dr. Wang joined Memorial Sloan Kettering Cancer Center in 2007, and is currently an Associate Lab Member in Department of Molecular Pharmacology, and the Assistant Director of the Michael G Harris Cell Therapy and Cell Engineering Facility. Dr. Wang is in charge of the R&D, process development and manufacturing. She has overseen the successful manufacturing of all the CAR T cell products used in 13 phase I/II clinical trials as well as over 20 batches of cGMP grade viral vectors. She served in the translational science and product development committee in the American Society of Gene and Cell Therapy (ASGCT). She is currently a member for the National Heart, Lung and Blood Institute (NHLBI) independent external panel and a committee member for the Alliance of Regenerate Medicine (ARM) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

Dr Mickey Koh received his medical degree in Singapore and all his subsequent specialist Haematology training including his FRCPath, MRCP and PhD in London. He holds several joint positions. Dr Koh is a Consultant Haematologist and Senior Lecturer at St George’s Hospital and Medical School, London, UK. He is also the Programme Director of the Stem Cell Transplant Programme as well as being the Clinical Lead for Bone Marrow Failures and Rare Haematological Diseases at St George’s Hospital.
At the same time, he is also the Programme Director of the Cell Therapy Facility in Singapore involved in cell therapy trials cross haemato-oncology and regenerative medicine. He was also previously the Deputy Director of the National Blood Service in Singapore
Dr Koh sits on the board of various transplant and cell therapy organizations including being the Chairperson of the Cell Therapy Working Party at International Society Blood Transfusion and Chairperson of the Graft Processing/Cellular Therapies subcommittee of Worldwide Network for Blood and Marrow Transplantation. He is a past Board member of the International Society of Cellular Therapy Therapy and is Vice _president of the ISCT presidential Task force on Unproven therapies. Dr Koh has also been an advisor to the World Health Organisation on matters of transfusion and cellular therapies. He is widely published and is also on the editorial board of various peer reveiwed journals

Dr. Steve Oh obtained his PhD from Birmingham University, UK (1990) and is the Director of Stem Cell Bioprocessing and Institute Scientist, Stem Cell Group. He is a recognised global leader in cell therapy and holds several industry leadership roles. He was past Asia Pacific Vice President of the International Society of Cell and Gene Therapy (ISCT); current member of the Process and Product Development Committee (PPD); Member of International Society of Stem Cell Research (ISSCR); Steering Committee Member of International Stem Cell Banking Initiative (ISCBI); Vice President of Stem Cell Society Singapore (SCSS). He is also an Adjunct Associate Professor at NTU, PhD Supervisor at A*STAR Graduate Academy and has received research funding grants totalling SGD 25 million. He holds 43 Patents, granted and pending, 120+ scientific publications, written the book “Sensational Stem Cell: How to cure medical complications.” and created 3 companies: Veristem, Zenzic Labs and SingCell.
Our research is focused on human adult and pluripotent stem cell bioprocessing. Our team has developed a range of patent families for the manufacture of mesenchymal stem cells, reprogrammed human induced pluripotent stem cells and created blood cells, neural cells, cardiomyocytes, cartilage, bone and retinal pigment epithelial cells at bioreactor scale using a range of microcarrier technologies including biodegradable ones. Most recently, we have achieved a novel method of directed differentiation using CRISPR technology that will accelerate therapeutic applications of stem cells. A complimentary technology that has been developed is the use of microfluidics for separations of cell and particulates.

Dr. Yoji Sato is Head of Division of Cell-Based Therapeutic Products, National Institute of Health Sciences. Dr. Sato is also an Adjunct Professor of Nagoya City University, a Guest Professor of Osaka University, and an Adjunct Professor of Kyushu University. He received his Ph.D. in Pharmaceutical Science from the University of Tokyo. While a post-doctoral fellow at the University of Cincinnati College of Medicine, he succeeded in establishing a variety of transgenic animal models to elucidate mechanisms of cardiac excitation-contraction coupling and heart failure. Dr. Sato’s current research area is in the field of regulatory science for the quality and safety of advanced cell-based therapeutic products (CTPs). He is currently leading a public-private partnership initiative in Japan for validation of test methods for tumorigenicity assessment of CTPs. He is also serving as Vice Chair of Database Committee, the Japanese Society for Regenerative Medicine, which provides the National Regenerative Medicine Database (NRMD), a nation-wide patient registry system for CTPs, and as a member of Technical Committees, Panel on Science and Technology, Health Science Council, the Japan Ministry of Health Labour and Welfare.

Dr. Milone is an Associate Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine of the University of Pennsylvania. His research is focused on the development of engineered T cell immunotherapies. Dr. Milone is a co-inventor of tisagenlecleucel (CTL019, KymriahÒ), the first US FDA-approved gene therapy that employs T cells genetically modified with a chimeric antigen receptor (CAR) targeting CD19 for the treatment of B-cell malignancies. His research has led to over 150 pending and granted patents filed in the area of CAR technology and engineered T cell therapy. In addition to a major focus on cancer, Dr. Milone’s research also explores applications of engineered T cells to non-malignant disease, most notably antibody-mediated autoimmune disease. This research led to the development of chimeric autoantibody receptor (CAAR) technology in collaboration with Dr. Aimee Payne at the University of Pennsylvania. Dr. Milone is a scientific co-founder and co-chair of the Scientific Advisory Board Cabaletta Bio (NASDAQ: CABA) and Verismo Therapeutics that are developing technologies developed in his laboratory.
Dr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from New Jersey Medical School and UMDNJ-Graduate School of Biomedical Sciences. After an Internship in Internal Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training in clinical pathology, transfusion medicine and clinical chemistry/toxicology. In addition to his active research program, Dr. Milone is also a practicing clinical pathologist and Associate Director of the Toxicology Laboratory at the Hospital of the University of Pennsylvania.

Rafal has obtained a M.D. degree in 1996 and trained as a pediatric surgeon at Medical University in Lodz’s pediatric hospital. Until 2005 he was an assistant professor at the Department of Pediatric Surgery and Oncology. In 2005, he received a Japanese MEXT scholarship and started a doctoral course at Kobe University, where he became first interested in induced pluripotent stem cells (iPSC). After obtaining the Ph.D. degree in 2010, he held several postdoctoral positions in Japan and received an iPS cell generation and maintenance training at Kumamoto University. In January 2019, he joined the Research and Development Section in Facility for iPS Cell Therapy, Center for iPS Cell Research and Application, Kyoto University, headed by Prof. Shinya Yamanaka, where he is working on the manufacturing of iPS cells for clinical applications. In 2020, the facility became a core of newly established CiRA Foundation (https://www.cira-foundation.or.jp/e/), which is a public interest incorporated foundation intended to serve as a bridge between academia and industry. Currently, he is a principal investigator at the CiRA Foundation’s Research and Development Center.

永泰生物创始人、CEO
北京大学药学院客座教授
曾任中国人民解放军总医院肿瘤中心实验室主任
曾任北京大学肿瘤医院生物治疗中心主任
中国研究型医院协会肿瘤学专业委员会副主任委员
中国女医师协会细胞治疗专业委员会副主任委员
《中华微生物学和免疫学杂志》编委
北京市三八红旗手奖章、北京市科技新星、北京经济技术开发区亦麒麟领军人才获得者
王歈博士毕业于北京大学并获得免疫学博士学位，在医学研究领域拥有逾30年经验，曾在数家国内外研究机构担任研究员，曾任北京大学医学部免疫学系副教授、硕士生导师、北京大学临床肿瘤学院肿瘤生物诊断与治疗中心主任、301医院肿瘤中心实验室主任，美国乔治城大学、哥伦比亚大学、澳大利亚路德维格癌症研究所访问学者。
永泰生物制药有限公司创始人、执行董事兼首席执行官、联席首席科技官，负责管理本集团整体营运、制定本集团科学发展战略计划并统筹研发工作。在癌症医治领域取得了重要的研究成果：曾/现任17项国家及地方科学基金项目负责人，包括国家自然科学基金、国家“863”专项支持等；对肝癌抗原的原研成果，获多项肿瘤抗原专利，包括授权专利4项、正在受理的专利3项； 在癌症研究及免疫学相关学术期刊上发表了30余篇科学文章。

Wenshi received her MD of clinical medicine from Tianjin Medical University and her master and PhD on immunology and microbiology from Tianjin Medical University and Tongji Medical College of Huazhong Science & Technology University & Heidelberg University.
Wenshi’s work experience focuses on immune-oncology and cell therapy. Wenshi conducted her post-doc and research scientist training in City of Hope, University of Southern California (USC) and Moffitt Cancer Center.
Her experience of biotech and biopharma is CGT driven (Hemacare, Kite Pharma, Sangamo Therapeutics and Metagenomi). Wen¬shi Wang brings both inter¬na¬tion¬al and Amer-i¬can insti¬tu¬tion¬al drug devel¬op¬ment expe¬ri¬ence to her role at FosunKairos. She serves as SVP tech & Ops.
She has made sig¬nif¬i¬cant con¬tri¬bu¬tions to many suc¬cess¬ful fil¬ings with agen¬cies (Inter¬act, Pre-IND, IND/IMPD, Pre-BLA, NDA). Wenshi has published multiple research articles and patents.

博士，可瑞生物首席科学官&生产管理负责人。北京市科技新星，美国Drexel大学访问学者，美国乙肝基金会Blumberg研究所博士后。作为课题负责人承担多项国家自然科学基金、北京市自然科学基金和北京市科技计划项目课题；核心参与10余项国家科技重大专项、国家重点研发计划、前沿生物技术专项等重大课题。在国内外期刊发表高水平论著30余篇、获国家发明专利和计算机软件著作权10余项。长期致力于肿瘤免疫治疗创新蛋白药物和细胞药物的研发工作，并有丰富的免疫细胞治疗产品工艺开发和GMP生产管理经验，主导推进多款TCR-T细胞治疗产品进入注册临床和非注册临床研究阶段。

于涛，清华大学生物学博士，现任健达九州（北京）生物科技有限公司副总经理、核心新药管线负责人，北京健达四海医疗科技有限公司执行董事。自2010年开始进行神经生物学研究和神经系统疾病药物开发，专注于研发重大脑疾病的基因治疗解决方案，围绕重大脑疾病的基因治疗、药物递送、康复和评价开发相关的基因药物、医疗器械和医学方案。

毕业于北京大学医学部，获博士学位，眼部神经损伤的重建保护与康复北京市重点实验室副主任, 担任中国妇幼保健协会出生缺陷防治与分子遗传分会常务委员、中国医师协会眼科分会遗传眼病专业委员会委员等职。多年来，致力于遗传性眼病的临床和基础研究。作为课题负责人主持科技部十四五重大项目1项，国自然基金5项，北科委重点项目1项，发表SCI文章30余篇。主要研究内容有：
遗传性眼病基因诊断和生育预防：自主研发“遗传性眼病基因诊断芯片”，是国内最早开展遗传性视网膜变性（IRDs）临床基因诊断的课题组之一，目前已完成逾万例患者的基因检测，阳性率约70%，与国际范围内同行业领先水平持平；在基因诊断基础上，与北医三院生殖中心和产科合作，配合有效的产前诊断和PGD使多个患病家庭获得健康的孩子；
专病队列数据库：建立IRDs专病队列，总结出中国IRDs患者的基因突变频谱和突变热点，为基因治疗药物靶点筛选提供基础；基于大队列进行疾病自然病史研究，为基因治疗药物临床试验提供病例和外部对照；
新的致病基因研究：在基因诊断的基础上，收集由未知基因突变所致的遗传性眼病大家系样本，进行新的致病基因研究。本课题组首次发现 ADIPOR1 基因是常显遗传RP新的致病基因；
基因治疗药物研发：IRDs目前无有效疗法。创立中因科技，产学研深度融合，针对中国IRDs患者中常见的致病基因和突变热点，进行具有独立自主知识产权的基因治疗药物研发，包括基因替代治疗或基因编辑治疗。目前已授权PCT专利和发明专利10余项，ZVS101e项目已完成I/II期临床试验，ZVS203e项目已获得中美IND批件。

金子兵，眼科教授、主任医师、博导。首都医科大学附属北京同仁医院党委委员、副院长。入选The Macula Society member，中国遗传学会眼科遗传病分会主任委员，中国医师协会眼科医师分会委员，中日医学科技交流学会眼科分会副会长，中华医学会眼科分会学组委员，北京医学会眼科分会常委、组长。在国家自然科学基金（含重大研究计划、杰青、优青等7项）等支持下，围绕眼科疾病新发现十余个致病基因，在国内率先推动眼科CGT发展。全职回国以来，在PNAS(5)、Nat Commun(3)、Sci Adv(2)、eLife等期刊发表学术论文多篇，其中封面文章9篇,被引7600多次（谷歌），H-index 42，连续三年入选斯坦福前2%顶尖科学家。以第一完成人获得浙江省自然科学一等奖、教育部自然科学奖二等奖和中国出生缺陷防治基金会科技进步一等奖等。任《眼科》杂志执行主编，《IOVS》《Experimental Eye Research》《Asia-Pacific Journal of Ophthalmology》执行编委。曾获国家万人计划领军人才、科技部中青年科技创新领军人才、国家百千万人才工程、有突出贡献中青年专家、青年北京学者、中国青年科技奖、中国驻日大使奖等。

Dr. Xiang received his Ph.D. degree in 2013 from Jinan University, China. He worked as a postdoc at Yale Stem Cell Center and the Department of Genetics at Yale University from 2013 to 2019 and associate research scientist from 2019 to 2020. Dr. Xiang joined the School of Life Science and Technology at ShanghaiTech University as a tenure-track assistant professor in March 2020. His main research topic in the past decade includes the development and application of brain region-specific organoids and complex brain organoid models based on human pluripotent stem cells. Dr. Xiang developed some of the early models of cross-brain-region neural circuits and organoid vascularization, by incorporating distinct brain region-specific organoids and cell fate programming. His work has been highlighted in a line of articles and organoid-themed collections of prestigious journals, including introduced on the topic Methods to Watch 2021 by Nature Methods.

Dr. Zhen-Ge Luo, Professor, Executive Dean, School of Life Science and Technology, ShanghaiTech University.
Dr. Luo graduated from Nankai University in Tianjin, China in 1988. He obtained Ph.D from Chinese Academy of Military Medical Sciences and accepted postdoctoral training in the Department of Neurobiology, University of Alabama at Birmingham (UAB), the United States of America. In 2003, he joined the Institute of Neuroscience (ION), Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), as a Principal Investigator. In 2018, he joined School of Life Science and Technology, ShanghaiTech University, as a tenured full professor. His research concentrates on neural development, degeneration, and regeneration, including cortex development and evolution, neuronal growth and repair, aging related neuronal disorders. Currently, Dr. Luo serves as a vice president for the Chinese Society for Cell Biology, an executive council member of the Chinese Neuroscience Society chairing the Neurodevelopment and Regeneration Branch.

Dr. Zhigang Tian’s laboratory is credited with seminal discoveries regarding basic knowledge of natural killer (NK) cells and NK cell-based immunotherapy. In 2008 and 2019, he won National Natural Science Award, and in 2011, he won National Scientific and Technological Progress Award. Since the outstanding contributions in the field of NK cell research, Dr. Tian was elected as a member of the Chinese Academy of Engineering in 2017 and a member of the Academia Europaea in 2022.
Dr. Tian is currently professor at University of Science and Technology of China (USTC) in Hefei, China, where he also served as a Deputy Director of the Academic Committee of USTC, Director of Institute of Immunology, Director of The Key Lab of Innate Immunity and Chronic Diseases of Chinese Academy of Science (CAS), and President of the Institute of Health and Medicine, Hefei Comprehensive National Science Center.
Dr. Tian is the former President of Chinese Society of Immunology, and the former Council member of International Union of Immunological Societies (IUIS).

许田教授在1993到2018年历任耶鲁大学遗传学和神经生物学助理教授、副教授、终身教授、C.N.H. Long讲席教授，及耶鲁大学遗传学系副系主任、耶鲁大学校长顾问，1996-2018年历任复旦大学兼职教授、长江讲座教授、发育生物学研究所所长、国家发育与疾病国际合作研究中心主任。许田教授长期担任Cell、Annual Review of Genetics、Molecular CancerResearch、Integrative Biology、The International Journal of Biological Sciences等杂志编委，Disease Models and Mechanisms创刊编委。许田教授曾任华人生物学家协会主席，获美国优秀博士后奖(Whitney)、美国优秀青年科学家学者(Pew)、霍华德休斯研究员、结节性硬化症协会创新奖和杰出贡献奖、美国科学促进会成员(AAAS Fellow)等奖项。许田教授不仅是LAM、Drug Farm、Double Rainbow、FosunLead、GeCell等科技公司的创始人，也是CuraGen、Butterfly、Hyperfine、Quantum-Si等公司顾问。
From 1993 to 2018, Prof. Tian Xu served as an assistant professor, associate professor, tenured professor, CNH Long Chair Professor, associate dean of the Department of Genetics and Neurobiology and advisor to President at Yale University. From 1996 to 2018, Prof. Xu served as adjunct professor at Fudan University, Chair Professor of the Yangtze River, Director of the Institute of Developmental Biology, and Director of the International Cooperation Research Centre for National Development and Disease. Prof. Xu has been a long-term editorial board member of the magazines, Annual Review of Genetics, Molecular Cancer Research, Integrative Biology, The International Journal of Biological Sciences, and the editorial board of Disease Models and Mechanisms. He has served as chairman of Chinese Association of Biologists. He was awarded the American Outstanding Postdoctoral Award (Whitney), American Outstanding Young Scientists Scholar (Pew), Howard Hughes Fellow, Tuberculosis Sclerosis Association Innovation Award and Outstanding Contribution Award, and the American Association for the Advancement of Science (AAAS Fellow) and other awards. Prof. Xu is not only the founder of LAM, Drug Farm, Double Rainbow, Fosun Lead, GeCell and other technology companies, but also an advisor of companies such as CuraGen, Butterfly, Hyperfine, Quantum-Si, etc.

陈功教授是国家特聘专家，暨南大学粤港澳中枢神经再生研究院大脑修复中心主任。复旦大学毕业，中科院上海生理所神经生物学博士。美国耶鲁大学和斯坦福大学博士后。曾任宾夕法尼亚州立大学终身教授和冠名主任教授（Endowed Chair Professor， 讲席教授）。陈功教授领导的团队在国际上首次报导了用神经转录因子NeuroD1将大脑内源性星形胶质细胞原位高效地转化为功能性神经元这一里程碑工作，被干细胞顶尖杂志Cell Stem Cell评为2014年度最佳论文，为大脑修复开辟了全新的神经再生型基因疗法。2015年再次在Cell Stem Cell上发表小分子化合物诱导培养的人源胶质细胞高效转化为功能性神经元的工作，为开发利用脑内胶质细胞再生神经元的药物疗法奠定了基础。2020年又在国际上首次发表灵长类大脑原位神经再生的里程碑工作。陈功教授有一百多项发明专利申请，已经获得国际范围内的45项专利授权，涵盖中国，美国，欧盟，日本等国家。陈功教授是NeuExcell 神曦集团的科学创始人。NeuExcell 致力于运用神经再生型基因疗法治疗神经损伤和退行性疾病。2021年，NeuExcell与罗氏制药旗下的Spark达成了1.9亿美金的合作协议，共同开发治疗亨廷顿舞蹈症的基因治疗药物。NeuExcell 在2022年被著名生物技术杂志GEN评选为亚洲5大极具潜力的基因治疗公司。

合源生物科技（天津）有限公司 CEO
临床医学博士学位（内科血液病学），在肿瘤生物科学研究、创新药研发与商业化领域拥有超过20年经验。
2018年参与创立合源生物并担任首席执行官。凭借对细胞基因前沿创新技术发展和创新药研发及商业化路径的深刻洞见，搭建了具有国际竞争力的多疾病领域的细胞治疗产品管线和专业团队，以临床价值为导，向带领公司稳步实现从细胞药物研发到商业化、并逐步实现全球化的战略布局，致力于将公司打造成为全球领先的专注于细胞基因领域的生物制药企业。
在吕璐璐博士的带领下，公司首个具有完全中国自主知识产权的核心产品，纳基奥仑赛注射液（CNCT19细胞注射液）获得国家药品监督管理局“突破性治疗药物”（2020）认定和美国FDA“孤儿药”（2022）认定，其新药上市申请（NDA）于2022年12月获得国家药品监督管理局正式受理并纳入优先审评，该产品是中国白血病治疗领域首个获得NDA受理并有望首个获批的CAR-T细胞治疗产品，也是有望首个获批的中国全自主研发的靶向CD19 CAR-T细胞治疗产品。
2007年以前，主要从事造血干细胞和间充质干细胞临床和科研工作。
2007年~2018年，在诺华、健赞、罗氏、阿斯利康和默沙东等跨国公司关键岗位任职，从事血液和肿瘤领域创新药物研发和产品商业化工作。

张春博士毕业于美国佛罗里达大学，在世界腺相关病毒（AAV）载体，基因治疗奠基人的实验室工作学习多年，至今已有20年的AAV研究开发经历。目前，在中国科学院苏州生物医学工程技术研究所担任研究员，博士生导师。张春博士创立了苏州吉恒基因科技有限公司。近年来，重点研究创新了高效安全AAV载体包装生产，大基因AAV基因治疗，有效AAV基因编辑领域里的多个重要技术。张春博士聚焦解决AAV基因治疗的根本问题，立足AAV基因治疗的长期发展，努力将AAV载体发展成为人类健康长寿载体。
Dr. Zhang earned his Ph.D. from University of Florida. He was a faculty member in Dr. Berns’ lab and studied AAV gene therapy. Now, Dr. Zhang is a professor at Suzhou Institute of Biomedical Engineering and Technology, CAS. For 20 years, Dr. Zhang has focused on research and product development of rAAV vector, AAV gene therapy and AAV gene editing. Significant breakthroughs have been made and innovative rAAV technologies have been developed, which will greatly facilitate the success of AAV gene therapy. Dr. Zhang has a vision of developing AAV vector into a human health vector.

Founder of Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd
Director of the Institute of Biomedical Engineering and Technology at East China Normal University
Member of the Cell Therapy Professional Committee of China Research-oriented Society
· Medical: Graduated from Fudan University Medical School，6 years of experience as a cardiac surgeon at Zhongshan Hospital.
· Basic research: Ph.D., Department of Medical Microbiology and Immunology, University of Alberta, Canada, and Division of Pediatric Molecular Genetics Center, University of California, San Diego, studied gene therapy under Professor Theodore Friedmann, the father of American "gene therapy".
· Pharmaceutical: Formerly an associate professor of Pharmaceutical Chemistry and Pharmaceutical Sciences at the University of Utah, USA.
· Entrepreneurship: Co-founded Nisshin Electric Technical Corporation, a US-Japan joint venture, and served as Vice President.
· Academic: "Zijiang Distinguished Professor" of East China Normal University, set up pharmacy specialty, and set up biomedical engineering and technology research institute.
· Domestic Entrepreneurship: Established Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd, which is the leading enterprise of CAR-T technology innovation in China, and has successfully carried out CAR-T clinical research on more than 1,000 patients with hematological tumors and solid tumors.

Dr. Yuxuan Wu, Founder and CEO of YolTech Therapeutics, Professor at East China Normal University. Dr. Wu developed CRISPR/Cas9 based Gene Editing system in hematopoietic stem cells and led the first CRISPR/Cas9 Gene editing treatment for patients with β0/β0 thalassemia, achieving great clinical outcome with patients’ Long term recovery of hemoglobin (Published in Nature, Aug.2022). With more than ten years’ expertise and practice in Gene Editing, Dr. Wu founded YolTech Thepapeutics in 2021 in Shanghai, devoted to advancing in vivo Gene Therapy in treating patients suffering serious diseases with feasible therapeutic solutions.

Juventas Cell Therapy， CTO
Novartis, Global Quality Auditor
MSKCC, Quality & Operations Manager
Vivaldi Biosciences, GMP Production Manager
Hebrew University of Jerusalem, PhD
Cornell University and Iowa State University, Postdoc
15 years hands-on experiences in CAR-T cell therapy，including clinical research & development, GMP manufacturing, vein-to-vein quality management, product launch & commercialization.

Dr. Lei Guo, Founder and CSO of BioT Beijing Therapeutics, Post-Doctor and Instructor of Harvard Medical School, Pathophysiology Professor Of Zhejiang University Medical School. Dr. Guo Founded several biotech companies including BioT Beijing Therapeutics, a company devoted in developing multiple strategies and techniques of mRNA delivery systems and in vivo CAR Therapeutics.

• 2020 to Present: UTC Therapeutics Inc., Co-founder, Chairman and Chief Scientific Officer
• From 2009 to 2019: Served as the director of the T cell engineering laboratory and an associate professor of the Department of Pathology at the Center for Cellular Immunotherapy at the University of Pennsylvania.
• Participated in the development and commercialization of Kymriah, the world's first CAR T cell product.
• led the research and development of RNA CART cell technology and carried out the world's first RNA CAR T cell treatment of cancer patients in 2010.
• led the R&D and process development of the world's first (US) regulatory-approved CRISPR gene editing clinical trial, and the clinical research results have been published in Science.
• Published more than 50 research papers, including in Science, Nature, Clinical Cancer Research, Molecular Therapy, Cancer Immunology Research, Protein Cell, Cancer Research and other journals.
• Filed More than 130 patents, ranking 7th in the global CAR T patent ranking according to the statistics of Nature Biotechnology in 2019.
• In 2015, co-founded Tmunity Therapeutics and was the founder of the company's core technology.
• From 2003 to 2008, As a Senior Research Fellow in Rosenberg Laboratory at National Cancer Institute (NCI), engaged in the research of TCR-T and CAR T. Guided and participated in the research and development of Yescarta CD19 CAR T. Published a total of 17 articles, 6 of which were the first author and participated in the research and development of 5 clinical trials.
• From 2000 to 2002, worked as a research assistant in the Department of Surgery of Duke University in the United States, and was engaged in tumor immunotherapy by RNA electroporation of dendritic cells.
• From 1996 to 2000, Worked at the Department of Immunology of the Weizmann Institute of Science in Israel as a postdoctoral researcher on bone marrow allograft transplant immune tolerance.
• In 1994, received a Ph.D. in Transplantation Immunology from the Third Military Medical University

Dr. Zhang Hongbing is an experienced scientist with over 20 years of expertise in drug research and development, particularly in the field of cancer immunotherapy. As the Vice President of Research at Eureka Therapeutics Inc., he oversees the company's antibody and cellular immunotherapy drug research and development, as well as strategic external R&D collaborations.
Throughout his career, Dr. Zhang has led the development of several macromolecular drugs and cell therapy drugs from early discovery to preclinical/translational product development and hold many international patents. He has worked in various biotechnology companies from start-up to publicly traded, including Xenogen Corporation, Chiron Corporation and Five Prime Therapeutics Inc. The macromolecular and cell therapy drug projects he has led have turned into strategic collaborations with large pharmaceutical companies for various start-up companies.
Dr. Zhang received his bachelor's degree from the Department of Biology (now the School of Life Sciences) of Peking University in 1988, and his Ph.D. in Molecular Genetics from Baylor College of Medicine, Texas, USA in 1995.

Dr. Wenbo Wang was trained in Shanghai Institute of Materia Medica, CAS as a master student and obtained his PhD degree from DKFZ (German cancer research center) and Heidelberg University in 2015. He worked as a postdoc. associate in the Jackson laboratory and the University of Pennsylvania. In Upenn, he worked under the supervision of Prof. Yangbing Zhao and Prof. Carl June studying novel TCRs, novel aAPCs model generation and T cell genome editing. He then joined National Research Center for Translational Medicine, Shanghai Ruijin Hospital as a Co-PI and led the study of combination therapy with TCR-T and NK cells and adverse effects of CAR-T cell therapy. In 2018, he joined Curegenetics as VP of translational medicine and led a group focusing on TCR engineering and novel CAR-T cell therapies. In 2021, he founded LeaLing Biopharma and serves as CEO. He has years of experiences in TCR based therapies and other cellular therapies. He invented fast cloning technologies of TCR full length which facilitates the R&D of personalized TCR-T and other TCR based therapies. He also filed over 20 patents focusing on novel TCRs and CARs, TCR cloning and sequencing, T cell engineering and other novel cellular therapies and published over 10 papers in famed biomedical journals.

周鹏辉，广州泛恩生物创始人、董事长，密西根大学免疫学博士，哈佛大学医学院博士后，中山大学肿瘤防治中心、华南肿瘤学国家重点实验室教授、博士生导师。入选国家“万人计划”领军人才、国家“海外高层次人才引进计划”、广东省“珠江人才计划”领军人才、广州市开发区“创业领军人才”。长期从事实体肿瘤免疫治疗药物开发与临床应用，鉴定了肿瘤微环境抑制T细胞的关键信号通路与基因，为逆转实体肿瘤微环境提供了高效的解决方案；发现了肿瘤抗原特异T细胞的分子标志物，建立了快速获取自体抗肿瘤T细胞与TCR的核心技术；多项专利转化为产品。开发了准确筛选免疫治疗有效患者的诊断试剂盒；研制了“个体化TCR-T细胞治疗”、“逆转实体肿瘤微环境的TCR-T细胞治疗”、“TAL-T细胞治疗”等新型免疫治疗方法与药物，进入了Ⅰ期临床试验。研究成果发表于Nature、Cell、Nature Medicine、Cell Research、JCI、PNAS等高水平国际学术期刊。

Dr Yi Li graduated from XiangYa School of Medicine, CSU and gained his Ph.D at University of Leicester, UK, has served as Chairman and CSO at TIOC therapeutics Ltd, Principle Investigator at Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences. Dr Li’s main research interest is immunotherapy, especially focus on optimizing T cell receptors and manipulating immune microenvironment for advanced therapeutic strategies. Represented studies of Dr Li were published in Nature Biotechnology, Nature Medicine, JBC, Molecular Cancer Therapy and Immunology etc. Dr Li provided major contributions to the world first TCR based drug Kimmtrak approved by FDA, USA, and the first TCR-T IND TAEST16001 approved by NMPA, China.

韩研妍，博士，恒瑞源正生物科技有限公司 首席科学家
德国慕尼黑大学医学院人类生物学博士，慕尼黑工业大学肿瘤免疫学博士后，中欧EMBA。深圳市领军人才，深圳市孔雀计划人才。国家科技部重大专项，973重大项目的主要承担者，国家面上项目，深圳科创项目等产业项目的负责人。
恒瑞源正生物科技有限公司成立于2015年，是一家专注于实体瘤的免疫疗法的生物制药公司。恒瑞源正由恒瑞集团和深圳源正细胞合资成立，公司总部位于上海，在广州和深圳设有全资子公司，拥有研发中心和GMP级细胞制备车间，总面积近13000平方米。恒瑞源正已在中国、美国、日本和欧盟等国家或地区申请了多项发明专利并获得授权。公司拥有自主知识产权的实体瘤免疫细胞疗法 MASCT-I 已经完成了注册一期临床试验，目前已经进入注册二期临床试验阶段。该公司首款具有自主知识产权的TCR-T产品HRYZ-T101注射液已经向CDE提交IND申请并获得受理。

何霆 艺妙神州创始人兼CEO
何霆，清华大学生物学博士，高级职称，2015年创办北京艺妙神州医药科技有限公司，专注基因细胞药物的研制，坚持以“让癌症不再是绝症”为使命，从0到1打造一支一流的基因细胞药物研发团队，构建了领先的基因细胞药物一站式技术平台；带领团队取得了北京市首张 CAR-T 药品生产许可证，自主研发的1类抗肿瘤新药 IM19 CAR-T 细胞注射液，获得国家药监局颁发的3个临床试验批件，有望成为同类首款自主原研的CAR-T药物。艺妙神州获得多家知名投资机构青睐，累计完成9轮超10亿元的融资，股东包括中国人寿、中国太平、国投创业、龙门基金、中关村科学城基金、首钢基金、北创投、首都科技发展集团、同创伟业、夏尔巴投资、盛景嘉成、广发乾和等。
作为项目负责人，承担了国家科技部-重点研发计划专项、北京市科委-G20工程重大新药创制项目、北京市科委-医药创新品种及平台培育项目、北京市经信局-高精尖产业项目、北京市科技新星计划、中关村前沿企业支持项目和北京市科技型中小企业促进专项等政府科研项目。
曾获中关村高端领军人才、北京市科技新星、北京市海英人才、北京市雏鹰人才、北京市青年人才、麻省理工科技评论“35岁以下科技创新35人”、《财富》“中国40位40岁以下商界精英”、全国颠覆性技术创新大赛优胜奖、清华大学校长杯金奖等荣誉。
作为研发和技术带头人，获得30多项技术专利授权，自主研发整套基因细胞药物技术平台，支撑起多种主流基因细胞药物的创新开发；在国际学术期刊发表十数篇该领域的SCI研究论文，受邀出席多个国际顶尖学术和产业会议并做主题演讲，包括美国临床肿瘤学会年会（ASCO）、美国血液学会年会（ASH）、亚洲细胞疗法制造学会年会、CAR-TCR亚洲峰会等。

曾任中国科学院北京基因组研究所研究生导师、2015年度国家十三五传染病重大专项首席科学家；参加十一五重大药物研发专项、承担十二五、十三五 “重大新药”创制项目；目前主持多项科技部和地方科委课题。国家和浙江、福建等省自然科学基金委评审专家；多个杂志编委；发表SCI论文 50余篇。

高晓飞博士是西湖生物医药科技（杭州）有限公司（Westlake Therapeutics，以下简称“西湖生物医药”）的创始人，于2017年回国加入西湖大学组建自己的团队，基于以填补国内未被满足临床需求为目标，并借助于在打造工程化红细胞药物技术平台REDx上取得的突破，高博士和创业团队于2019年1月创立了西湖生物医药，西湖生物医药专注于将在研阶段的创新红细胞疗法推向临床开发，产品布局以靶向免疫代谢、癌症治疗为主线，以提高患者生存及生活质量为目的，开发疗效显著且安全可靠价优的新药治疗方案。
高博士拥有20年以上在中国和美国顶尖科研院所从事学术科研及生物创新药研发的经验，且科研成果成功获得产业转化应用。高博士在美国堪萨斯大学获得博士学位、于美国麻省理工学院完成博士后研究。

浙江大学/第二军医大学医学免疫学国家重点实验室博士，讲师。十五年从事CAR-T、NK、TIL、DC、TCR-T等多种细胞肿瘤治疗从研发到临床的经验。曾负责中国首个CAR-T细胞治疗恶性血液肿瘤I/II期注册临床启动并推进至II期，同时负责推进三个CAR-T细胞治疗的注册临床及TCR-T及TIL细胞治疗实体瘤IIT临床研究。参与了中国首个获取CFDA批准的细胞治疗产品“抗原致敏的树突状细胞治疗转移性大肠癌”Ⅱ/Ⅲ期临床试验（2006 -2018）。在高企及CRO公司负责在整个细胞治疗临床试验周期前期研发，IND申报，医学研究、临床运营、及药物警戒等方面管理。作为主要负责人员参与科技部863重大专项 “细胞治疗关键技术及产品研发”主题项目、科技部重大新药创制“大肠癌树突状细胞治疗性疫苗的临床研究”、承担并参与多项国家自然科学基金、上海市科委重点攻关等多项与细胞免疫治疗肿瘤的项目研究。以第一作者在Biomaterials、 Cell Mol Immunol、J Biol Chem、Mol Ther. 等杂志发表多篇论文，申请免疫治疗相关专利多项。

Dr. Chen got his bachelor and Ph.D degrees from Wuhan University. He went on and did postdoctoral work on tumor immunotherapy at Duke University. Dr. Chen co-founded Hervor Therapeutics in 2021 as VP of R&D. Before that he was at TCRCure and led TCRCure US R&D department.
Dr. Chen has extensive experience in cell therapy drug development, he led the development of a global FIC CAR-T product for Ovarian and Endometrial Cancer, a FIC anti-PD1-armored TCR-T product and many other CGT platforms.

李志远，博士，高级工程师，毕业于中国科学院大学上海巴斯德研究所。曾先后在西比曼生物科技（上海）有限公司、信达生物（苏州）有限公司担任高级研发经理、功能生物学副总监等职务，现任普米斯生物功能生物学与细胞治疗总监。在免疫及细胞治疗领域拥有近15年的研究经验，在靶向CD19、CD20、BCMA、MSLN、CLDN 18.2等众多血液肿瘤与实体肿瘤相关靶点的细胞治疗产品开发方面拥有丰富经验。在信达生物工作期间，领导了细胞治疗相关项目抗BCMA全人源单链抗体筛选工作；目前，该项目相关CAR-T产品处于NDA阶段。入职普米斯后，领导开发了可应用于实体肿瘤临床治疗的CAB-T细胞治疗平台，基于此平台开发的多个细胞治疗产品已进入非注册临床研究（IIT）阶段。

Chelsie He, the Founder and CEO of Suzhou GenAssist, is an expert in drug discovery and a veteran in healthcare investment and incubation. Dr. He received her Ph.D degree in immunology, Shanghai Jiao Tong University and MBA from the Alian Manchester Business School. She has won Entrepreneurship Leading Talents of Suzhou Industrial Park and Gusu Talents. GenAssist is the first Chinese company dedicated to the development of base editing gene therapy drugs against rare diseases. Chelsie He is currently leading GenAssist to develop various first-in-class base editing gene therapy drugs. The first indication of Duchenne muscular dystrophy (DMD) has entered the IND enabling stage, which is currently the latest DMD base editor drug in the world. Dr. He has more than ten years’ experience in drug R&D and production, and eight years’ experience in Investment and Business Development. She served as the Managing Director in Fosun Innovation Center, Investment director in Sunshine Insurance Co., Ltd and Product Planning director in Tasly Group. By leveraging her expertise both in academia and industry, she successfully led more than 10 licensing deals and M&A projects.

Dr. Jingmin Zhou is the CEO & Co-Founder of Genemagic Biosciences, a startup focuses on neuro regeneration to cure patients with CNS diseases. Before he joined Genemagic, he served as Senior Director of Process & Analytical Development at Prevail therapeutics, a wholly Eli Lilly owned subsidiary, he also served different CMC roles at Axovant, Spark & Intrexon. With 17 years of CMC experience on AAV, he has contributed more than 10 approved INDs and 1 successful BLA (Luxturna) by FDA & EMA. Jingmin is a member of USP’s AAV Gene Therapy Expert Panel (2021-2025), responsible for developing best-practice guidelines on AAV vector design, manufacturing, quality control and regulatory considerations.

马一介博士是北海康成的高级总监，商务拓展和战略合作主管。他领导和管理公司的全球合作与交易。他同时还负责公司的基因疗法战略。他在生命科学领域的基础研究、创业、投资、战略咨询和商务拓展方面拥有超过 20 年的综合经验。此前，他曾在全球战略咨询公司 Trinity Life Sciences 工作，为各阶段生物制药企业，包括赛诺菲、强生、渤健、福泰制药等在内的世界财富 500 强公司提供战略咨询，并为价值从 5亿到 10 亿美元以上的投资和交易机会提供评估与建议。在此之前，他曾在波士顿的一家生物科技投资基金工作，并与他人共同创立了一家聚焦精准医疗的初创公司，并获得风险投资。他曾是病毒免疫学科学家，在美国伊利诺伊大学医学院完成了博士学位，并师从于国际著名病毒学家Elliott Kieff教授在哈佛大学医学院及布莱根和妇女医院完成了博士后研究。曾在Cell Host&Microbe、Cell Metabolism、美国国家科学院院刊等国际知名期刊发表科学论文30余篇，全球引用2000余次。
Dr. Yijie Ma is the Senior Director, Head of Business Development - Strategic Partnerships at CANbridge Pharmaceuticals, where he leads and manages global partnerships and transactions. He is also responsible for driving the gene therapy strategy of the company. He has more than 20 years of combined experiences in research, entrepreneurship, investing, strategy consulting and business development in the life sciences field. Previously, he worked at Trinity Life Sciences, a global life sciences strategy consulting firm, and provided strategic advice to clients ranging from startups to Fortune 500 biopharma companies across a wide range of therapeutic areas including Sanofi, Johnson & Johnson, Biogen, Vertex etc. He advised on investment and BD&licensing opportunities valued from $500M to $1B+ USD. Prior to that, he worked in a biotech investment fund in Boston and had co-founded a venture-backed precision medicine startup. He was trained as a viral immunologist and completed his PhD at the University of Illinois College of Medicine and postdoc research under the mentorship of Dr. Elliott Kieff, a world-renowned expert in Epstein-Barr virus, at the Harvard Medical School and Brigham and Women’s Hospital. He has authored more than 30 scientific publications in internationally renowned journals such as Cell Host&Microbe, Cell Metabolism, PNAS and so on with more than 2000 worldwide citations

赵春林 博士，安龙基金创始合伙人，安龙生物创始人，为清华大学生物系首届毕业生，获得美国匹兹堡医学院分子生物学博士和芝加哥大学工商管理硕士，曾任美国辉瑞制药资深经理，国科嘉和及康桥资本董事总经理，拥有三十多年生命科学及医疗健康领域的创业和投资经验，投资过信达生物，贝瑞合康，天镜生物，歌礼药业，莱凯医药，创响生物及国科恒泰等杰出企业。赵春林博士曾任清华大学生命科学院，医学院及药学院首届校友会主席，为百华协会资深会员。 安龙基金是一只专注于国内早期生命科学与医疗健康领域的基金，投资领域横跨生命科学，医药研发，医疗器械，医疗服务及相关领域。 安龙生物是国内核酸药物领先企业，专注基因治疗，RNA，基因编辑等核酸药物的新药研发。专业之外，赵春林博士喜欢足球，滑雪，曾做过DJ，拥有三个漂亮可爱的女儿。
Chunlin Zhao, Ph.D
Founder of the AnlongMed/AnlongBio. Dr. Zhao is among the first class graduated from Biological Science and Technology department at Tsinghua University in 1990. Then, he received his Ph.D of molecular biology at University of Pittsburgh School of Medicine and MBA from University of Chicago in the United States. Dr. Zhao was a senior manager at Pfizer in US. After returning to China, he founded Beijing LongMed biological technology co., LTD and then became partner of CASH Capital and C-Bridge Capital. Dr. Zhao has over 30 years of industry experience and excellent investment achievements, invested in Innovent, BerryGenomics, ASLETIS, GKHT and Imagine. Dr. Zhao is the founding Chairman of Tsinghua Alumni Association of School of Life Sciences，School of Medicine and School of Pharmaceutical Sciences, a senior member of BayHelix group. AnlongMed is a leading fund in Chinese life sciences and health care, focusing on biotech & pharma, medical devices, life sciences and medical services in China. Dr. Zhao also founded AnlongBio, a leading player in genetic medicine discovery in China, focusing on gene therapy, iRNA, mRNA, and other genetic medicines. Outside of his professional life, Dr. Zhao is a DJ, soccer player, ski lover, and has three lovely daughters.

大学毕业于南京大学, 法国INSERM-巴黎第7大学分子生物学博士。
1996年加入 IBEX Pharmaceutical 公司，开发酶替代治疗产品。
2000-2006, Human Genome Sciences / Glaxosmithkline 带领40多人团队从事重组蛋白，抗体等产品的工艺开发、技术转移和 GMP生产。
2006-2011, Intercell/Valneva 公司领导 疫苗产品的工艺开发和GMP生产。
2012-2014，BioMerieux （生物梅里埃）美国的子公司Advanced BioSciences Laboratories (ABL inc)， 成功把公司从CRO 转型成CDMO 。专注做病毒产品的CMC开发，开发了几十个高难度的病毒产品的生产工艺和分析方法。包括： 慢病毒， Ebola-VLP，Adenovirus 和 基因治疗用的 AAV 载体 。
2015-2020，REGENXBIO inc 任AAV工艺开发总监，开发六个AAV产品 的生产工艺， 完成技术转让和GMP生产临床用的 AAV载体。 成功放大HEK293 悬浮细胞3质粒转染 生产工艺到2000L。是AAV生产工艺两个专利的第一作者。
2020.3月至今： 朗信生物CTO， 公司第一个AAV 基因治疗产品的IND 被CDE 受理；建立朗信生物的生产工艺平台/中试车间和质量系统， 完成了 3批次 200L 悬浮细胞的AAV生产， 将于2022年秋递交第二个AAC基因治疗产品的 IND。
张瑰宜博士有 25年北美生物制药公司的工艺和分析方法开发和 GMP生产经验。 成功拿到美国FDA 批准的 20 多个 IND， 2 个 BLA。

李斌 二级研究员、余㵑学者、上海交大特聘教授、国家基金委免疫学杰青、上海市领军人才、上海市优秀学科带头人，上海市免疫学研究所科研副所长&课题组长、中国细胞生物学学会常务理事、上海市欧美同学会生物医药分会会长、PENN Medicine China Club 副会长；European Journal of Immunology 执行副主编（2020）
主要研究方向：FOXP3+调节性T细胞及其临床应用。先后承担国家基金委杰出青年基金、重点项目（3项) 、移植免疫专项、中美及中波国际合作项目等；2009年回国以来，在国际一流学术刊物如 IMMUNITY、NAT IMMUNOL等发表FOXP3+Treg领域相关通讯及共同通讯作者论文一百余篇。
Bin Li, Ph.D. Yu He Scholar; Distinguished Professor of SJTU
Senior Investigator & Associate Director, Shanghai Institute of Immunology, Adjunct “Guangci” Professor, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University; President of the Biomedical Branch of the Shanghai Overseas Returned Scholars Association; Vice-President of PENN Medicine China Club;

魏继业博士毕业于中国科学院上海生理所（1991-1995年），师从杨雄里院士，获视觉脑科学博士学位，随后赴美国耶鲁大学医学院眼科中心从事博士后研究（1995-1998）， 并升任耶鲁大学眼科中心副研究员（1998-2001）,独立主持自己的实验室。自2001年，分别在美国Alcon（2001-2010）, Novartis （2010-2013, NIBR）, Intrexon (2013-2014)和Allergan(2014-2015)等多家著名跨国生物制药公司担任资深科学家，首席科学家和主任科学家。2018-2019年，他作为主持人（PI）赢得NIH基金一项（NIH STTR， President of Skyran Biologics， Philadelphia, PA, USA）。另外，他还赢得2012年诺华制药（Novartis）研究院火花创新奖。他自2015年9月担任新加坡国立眼科中心（SERI）及新加坡科技署分子细胞研究院（IMCB，A*STAR）新生血管项目(SIPRAD)联合所长（2015-2018），全权管理2000万美元BMRC国家基金及全球合作项目。旅美生活及工作20多年，在中国，美国和新加坡著名的大学及国际跨国公司担任领导职位。

胡荣宽，星锐医药创始人、董事长兼首席执行官。胡博士在核酸技术和药物研发方面拥有十余年的经验。在创立星锐医药之前，曾任职于石药集团、吉玛生物、中科院和诺和诺德，领导和参与了多个mRNA及siRNA药物研发项目，助推了国产第一款mRNA疫苗的获批上市。胡博士是50多项发明专利、研究论文的发明人和作者，荣获江苏省双创人才、姑苏领军人才、苏州园区科技领军人才等称号。他在中国科学技术大学获得博士学位，中欧国际工商学院EMBA，并曾于德克萨斯大学西南医学中心从事博士后研究。

Dr. Peter Xiaowen He has worked on R&D in the fields of immunotherapeutics, vaccine and cell-based products for more than twenty years with 25 patents and over 30 SCI published articles. Dr. He developed the therapeutic Serratia Marcescens formula approved by cFDA as Class I biological product and won the second prize of Science and Technology Progress Award for his development of therapeutic vaccine against hepatocellular carcinoma. Dr. He has been research professor and PIs in Stem Cell Center of New Jersey and Merck USA. Dr. He got a lot of funding from NIH and National Natural Science Foundation of China and led the teams to establish the key manufactory and quality control systems for cell-based therapeutics. Currently Dr. He worked as Co-founder and CSO in Origincell.

鼎新基因总经理，北京大学生理学博士。曾作为总裁参与基因治疗公司华毅乐健的孵化，主导了血友病A的AAV基因治疗项目的早期临床转化。 2020年联合创立上海鼎新基因科技有限公司，致力于递送技术驱动的创新基因治疗管线的开发，布局眼科、耳科、代谢等领域疾病。
General Manager of Shanghai Refreshgene Therapeutics, Ph.D. in Physiology from Peking University. As president, he participated in the incubation of gene therapy company Gritgen Therapeutics, and led the early clinical transformation of the AAV gene therapy program for hemophilia A. In 2020, he co-founded Refreshgene, which is committed to the development of innovative gene therapy pipelines driven by gene delivery technology in the fields of ophthalmologic, otologic, and metabolic diseases.

深圳市济因生物科技有限公司创始人、董事长兼CEO。
中国科学院大学博士。专注于通用型细胞与基因治疗产品开发，包括体内CAR-T与iPS来源NK细胞（CAR-iNK）制备技术研发。

陆道培医院医疗执行院长，北京陆道培血液病研究院院长
毕业于北京大学医学院，在美国内布拉斯加医学中心完成住院医，毕业于美国斯坦福大学血液及肿瘤专科
美国肿瘤以及血液病专科协会认证的血液及肿瘤专家，具有美国血液病专科医生，肿瘤专科医生执照以及中国行医执照
首都医科大学肿瘤学系第四届系务委员会委员
中国非公医疗机构协会第一届常务理事
中国非公立医疗机构协会血液病专业委员会主任委员
中国非公立医疗机构协会生物技术与细胞应用专业委员会常务委员
中国造血干细胞捐献者资料库专家委员会委员
中国临床肿瘤学会（CSCO）抗白血病联盟专家委员会常务委员
中国抗癌协会第一届血液病转化医学专业委员会常务委员
北京医学教育协会第七届理事会理事
医学界价值医疗泰山奖2021年度医疗管理奖获得者

Zhao Wei-Li, M.D., PhD, Professor of Hematology, First Deputy Director of Shanghai Institute of Hematology and Vice President of Shanghai Ruijin Hospital. She is the doctoral supervisor of both Shanghai Jiao Tong University and University Paris VII, foreign member of American Society of Hematology, Vice President of Chinese Association of Hematology, Secretary General of Chinese Society of Experimental Hematology, and member of the editorial committee of Pathobiology, Biomarker Research, Chinese Journal of Hematology, Chinese Journal of Leukemia & Lymphoma, and Clinical Hematology Journal. She mainly focuses on the clinical and basic research of hematological malignancies, especially the molecular mechanism and targeted therapy of malignant lymphoma. She innovatively proposed the molecular pathways of apoptosis, angiogenesis and cell differentiation involved in lymphoma progression and the availability of targeted agents for treatment. She has been awarded National Award for Science and Technology Progress and Outstanding Achievement Award of Scientific Research from National Ministry of Education and HUA XIA Award of Medicine and Technology from National Ministry of Science and Technology for her research progress and is now leading projects granted by National High Technology Research and Development Program of China, by National Natural Science Foundation of China and several other events on provincial level. She has been honored New Century Excellent Talents in University by State Ministry of Education, Rising-Star by Shanghai Committee of Science and Technology, Shu Guang Scholar by Shanghai Municipal Educational Committee. She has published over 108 articles including those on leading hematology journals like《CANCER CELL》、《NATURE GENETICS》、《BLOOD》、《MOLECULAR CANCER》、《SIGNAL TRANSDUCT TARGET THER》、《J HEMATOL ONCOL》、《LANCET HAEMATOL》、《CLIN CANCER RES》with total impact factors over 1200.

陈有海，免疫学博士，欧洲科学院（Academia Europaea）院士，美国医学与生物工程院（AIMBE）Fellow，国家特聘教授，教育部长江学者，基金委杰出青年学者。现任中科院深圳理工大学药学院讲席教授、院长。曾任美国宾夕法尼亚大学病理学和实验医学系终身教授，宾夕法尼亚大学医学院教学委员会主席，美国多发神经硬化基金会科学委员会主席等职务。主要从事癌症、炎症机制和治疗的研究，在免疫应答的调节、免疫性疾病的发病机制及治疗、新免疫检查点药物在癌症治疗中的应用等诸多领域取得显著的成就。在《Science》、《Cell》、《Nature》、《Nature Immunology》、《Nature Cancer》等国际权威杂志发表学术论文150余篇（截止到2022年H因子68； i10因子135；文章总引用次数～19000）。入选全球前1%顶尖科学家终身影响力榜单，是美国Kunkel学会会士（Elected Member），雷顿奖（Colyton Prize）获奖人。

He Huang, M.D., Ph.D., president of the First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University. Prof. Huang is also actively involved in and holds key positions in a number of professional organizations and scientific committees, including being Vice Chairman of Experts Committee of Chinese Marrow Donor Program; Executive Committee Member of Asia-Pacific Bone Marrow Transplantation Group (APBMT); Committee member of European Society of Hematology (EBMT); Committee member of Asian Cellular Therapy Organization(ACTO).
Prof. Huang specializes in clinical and basic research on hematopoietic stem cell transplantation, cellular immunotherapy and stem cell biology research. As corresponding author, he has published 213 original papers in SCI-cited journals including Nature, Blood etc. He has been awarded 19 national invention patents. He also organized APBMT annual meetings in 2005 and 2014 in Hangzhou, China as the chairman of the conferences. For his outstanding achievement on hematopoietic stem cell transplantation, Prof. Huang was awarded the national prizes by State Council twice in 2003 and 2015, respectively.

刘明耀，华东师范大学生命医学研究所所长，上海市调控生物学重点实验室主任。
1992 年，获美国马里兰大学(University of Maryland, College Park)细胞生物学博士 学位；1993 年到 1998 年，先后在美国约翰-霍普金斯大学医学院(Johns Hopkins University School of Medicine)和加州理工学院(California Institute of Technology)生 物学部做博士后研究。
1999 至 2007 年，先后在美国德克萨斯农工大学生命科学与技术研究所(Texas A&M University Institutes of Biosciences and Technology)任助理教授、副教授及终身正教授、 博士生导师；美国德州大学休斯顿医学院(UT Houston Medical School)，德州大学MD Anderson肿瘤中心(University of Texas MD Anderson Cancer Center)博士生导师。
2007 年，受聘回国加入华东师范大学，组建生命医学研究所并任所长；2011 年，组建上海市调控生物学重点实验室并任主任，同年起担任教育部创新团队带头人、国家重大科学研究计划（973 项目）首席科学家。2017 年起担任中国细胞生物学会肿瘤细胞分会会长，2020 年起任教育部科技委员会委员。
2012 年至 2020 年，担任华东师范大学生命科学学院院长，华师大-以色列海发大学科学与技术转化研究院院长。 刘明耀教授致力于 G 蛋白偶联受体（GPCR）在个体发育和重大疾病发生发展中的功能、机理及靶向药物研发，同时在基因编辑和细胞治疗的技术应用转化中做出卓越研究。回国后作为首席科学家先后主持国家973和重大科学研究计划（2 项）、国家自然科学基金重点项目（5项）、国家重大新药创制课题等。已在 Science、Nature、Nature Medicine、Nature Biotechnology、Nature Cell Biology、PNAS 等国际知名学术刊物上发表 SCI 论文 400 多篇，论文引用 2 万5千多次，H-Index 81，连续多年被评为高被引学者，申请专利 200 多项，授权 80 余项。
2012 年和 2017 年，分别获得国家科学技术进步一等奖和上海市科技进步一等奖，2014 年获得上海市白玉兰纪念奖，2021年获得华东师范大学首届杰出成就奖。

- Founder, Chairman and CEO, Neukio Biotherapeutics
- VP & CTO, Fosun Pharma
- Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years
- COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies.
- Head of Operations, GSK R&D Center in China
- Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China
- Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA
- Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA
Richard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.

Zefeng Wang is a principal investigator and the CAS Shanghai Institute for Nutrition and Health, and scientific founder of CirCode BioMed and Enzerna Bioscience Inc. Zefeng received his bachelor degrees as double major in Biological Science and Computer Technology from Tsinghua University, and a PhD degree at Johns Hopkins University. After working as a Damon Runyon post-doc fellow at MIT, he became an assistant professor at UNC at Chapel Hill in 2007 and was promoted to associate professor with tenure in 2013. In 2015, he moved his lab to Shanghai and became the director of CAS-MPG Partner Institute for Computational Biology (PICB), a partner institute jointly run by Chinese Academy of Science (CAS) and Max-Planck-Gesellschaft (MPG), which was merged to SINH in 2021. He is also the director of CAS key lab in computational biology.
As a scientist and an entrepreneur, Zefeng’s research focuses on the system biology of RNAs. He has made significant contribution to the filed of RNA biology by developing a series of genomic approaches to study RNA splicing and dysregulation in a systematic fashion. His lab is the first group to discover that circular RNAs can be translated inside cells, and further studies the regulatory mechanism of circRNA translation. He has also pioneered the filed of engineering RNA binding proteins to specifically manipulate RNA metabolism, which can be used as a research tool or potential therapeutic reagents. Based on the technology developed in his lab, he has founded two Biotech companies focusing on the development of new therapeutics using circRNAs and the engineered RNA binding proteins. He has published >70 research papers that were cited >9000 time, and served on the editorial board of dozens of journals (including Genome Biology, JBC, BBA, Molecular Cancer, etc.). His work was recognized by several research awards, including RNA Society/Scaringe Young Scientist Award, Alfred Sloan Research Fellow, Kimmel Scholar Award, Beckman Young Investigator, Max-Planck Fellow, Mercator fellow and MOST innovation team leader.

北京卡替医疗技术有限公司、北京智因东方转化医学研究中心创始人兼董事长；
基因修饰的外周血类TIL——ScTIL细胞疗法专利技术发明人，ScTIL是通过外周血富集类TIL细胞，通过基因改造之后可逆转肿瘤微环境，并且可在体内扩增的创新细胞疗法，无需依赖手术组织获取TIL细胞，几乎可适用于所有肿瘤患者。
单细胞全长测序技术带头人——通过自主研发制造的微流控芯片和微球标记系统，可同时检测海量细胞中每个单细胞的“突变+表达”，从而绘制突变细胞行为图谱，推进重大疾病机制研究。
承担十三五、十四五国家重点研发计划项目、北京市颠覆性创新课题等多个国家级重点项目， 省级科技进步一等奖获得者
参与上百篇学术论文发表，累计影响因子>300
中国生命关怀协会理事/精准医疗与细胞治疗分会副主委
中国医促会出生缺陷精准医学分会常务理事

第二军医大学医学学士, 加拿大阿尔伯塔大学免疫学博士。曾任上海长海医院医生，美国麻省大学医学院讲师及研究助理教授，上海恒瑞医药细胞免疫治疗部负责人，国家科技部肿瘤免疫治疗重大攻关项目PI。现为亘喜生物SVP和研发负责人。

华毅乐健总裁&联合创始人。吴凤岚博士在医药领域拥有丰富的产业和金融背景，在医药研发、资本运作、公司运营等方面有13年的实践经验。其曾在葛兰素史克、再鼎医药担任资深科学家近10年时间，承担6个临床前项目的IND申报。目前，这些项目已全部进入上市销售或临床试验阶段。后又在浩悦资本、华兴资本担任副总裁等职位，主导境内外多起生物科技公司私募融资。吴凤岚拥有同济医学院生物药学士学位，和上海交大医学院免疫学硕士及药学博士学位。

Dr. Wang received her Bachelor of Medicine from Shan Xi Medical University and Master of Medicine from China Medical University. She further earned her PhD in Cancer Biology from the National University of Singapore. She has over 20 years’ experience in the field of oncology in biopharmaceutical industry, clinical practice, and translational medical research. She led the Asia Pacific medical team for the successful launch of VENTANA PD-L1 assays at Roche Diagnostics APAC. She has driven autologous CD30 CAR-T cell therapy into clinical trials by leading the US FDA IND clearance to treat lymphoma at Tessa Therapeutics. Currently, she is Chief Operating Officer at Lion TCR, a Singapore biotech company developing first-in-class & best-in-class TCR T cell therapy against viral infections and their related cancers.

Dr. Wen (Maxwell) Wang currently is the Chief Executive Officer in IASO Biotherapeutics Co., Ltd. He obtained his M.D. degree in Wuerzburg University in Germany and Ph.D. degree from University of Aberdeen in UK and then did his postdoctoral training in at UConn Health Center in USA.
Dr. Wang has over 7 years of experience in Chinese Leading cell therapy companies including JW Therapeutics, Cellular Biomedicine Group (Nasdaq: CBMG) in clinical, preclinical, and translational development including CART cell and stem cell therapy. He held one of leading position in the 1st Chinese CD19-targeted CART cell and Mesenchymal Stem Cell INDs.
Before industry career, Dr. Wang worked as a Resident and Attending in Orthopedic Department in Shanghai TCM Hospital for 5 years.

Tongcun Zhang,PhD, Professor,Dean of College of Life Sciences and Health, Wuhan University of Science and Technology, Founder of Wuhan Bio-Raid Biotechnology Co., Ltd, was appointed as Distinguished Professor of "Chutian Scholar" and "100 Talents Program" in Hubei Province and Tianjin, "Yellow Crane Talent" and "3551" Talent Program of Optics Valley inWuhan Municipality.
Dr. Zhang actively contributes to a number of professional organizations and academic committees, including the senior member of the American Cancer Society, American Heart Association, and China Fermentation Industry Association, the Director of the Institute of Biochemistry and Molecular Biology in China, Distinguished expert of the Chinese Academy of Health Products, the permanent member of Biophysical Society in Hubei province, Director of the Institute of Biochemistry and Molecular Biology in Hubei province.
Dr. Zhang’s research focuses on molecular mechanisms of cardiovascular disease and CAR-T cell immunotherapy. He has hosted over 10 national, provincial, and ministerial projects, e.g. the National Major Research Program, the 863 Program, the 973 Program, and the National Natural Science Foundation of China, published over 150 papers in Nature, Blood,etc.,and been awarded 32 patents.

2011年，上海星华生物医药科技有限公司，董事长，首席科学家 2007年，上海复旦大学中山医院肿瘤生物治疗研究室主任，客座教授。进行免疫细胞治疗肿瘤方面的基础研究和临床应用
2005-2012，上海瑞金医院集团闵行区中心医院干细胞研究室主任，高级研究员。进行免疫细胞治疗肿瘤方面的基础研究和临床应用。发明三维培养装置，构建肿瘤类器官。
1987-2003，美国西南医学中心得克萨斯州苏格兰怀特儿童医院，先后任研究员，高级研究员及细胞和生物化学实验室主任。 1995年开始参与组织工程学方面的研究

杨林博士, 博生吉医药科技（苏州）有限公司创始人/董事长/CEO、博生吉安科细胞技术有限公司董事长兼CEO、兼职苏州大学唐仲英血液学研究中心特聘教授/博士生导师；苏州肿瘤免疫诊疗工程技术研究中心主任；曾兼任美国MD安德森癌症研究中心淋巴瘤/骨髓瘤系兼职教授。拥有20余年全球顶级癌症研究中心研发经验，是肿瘤生物学和免疫治疗领域的专家。荣获江苏省高层次创新创业领军人才、江苏省六大高峰人才团队、安徽省战略性新兴产业技术领军人才、中国创新创业大赛二等奖、创响中国安徽赛区第一名、庐州产业创新团队、合肥市创业领军人才等多项荣誉。在《Cancer Cell》、《Cancer Research》、《Oncogene》、《JBC》、《Cancer Science》等学术杂志发表论文80余篇。主持国家自然科学基金、科技部重大专项子课题、美国NIH SPORE子课题等项目。杨林博士致力于突破性 CAR-T细胞和CAR-NK细胞新药的研发以及肿瘤免疫细胞治疗技术的转化医学研究和产业化，率先在中国建设了以全自动CART细胞生产工艺为基础的、具有国际先进水平的产业化基地，并带领团队研发多个first-in-class 潜力的CAR-T细胞药物，包括已获批IND和美国FDA孤儿药认定的全球领先的CD7-CAR-T细胞、以及针对儿童实体肿瘤的、获得IND受理以及美国FDA孤儿药以及罕见病认定的B7-H3-CAR-T.
Lin Yang, Ph.D., the Founder and Chairman of PersonGen BioTherapeutics (Suzhou) Co., Ltd. Dr. Yang has more than 20 years of R&D experience in the world's top cancer research center, and is an expert in the field of tumor biology and immunotherapy. He has won many honors, including Innovation and Entrepreneurship Talents of Jiangsu Province, Six Peak Talent (Groups) of Jiangsu Province, Technical Talents of Anhui Province, Entrepreneurship Talents of Hefei, Luzhou Industrial Innovation Talent(Groups), Second Prize of China Innovation and Entrepreneurship Competition (2017), First Prize of Anhui Innovation and Entrepreneurship Competition(2017), etc. He has published more than 80 research articles in academic journals, including Cancer Cell, Cancer Research, Oncogene, JBC and Cancer Science, etc. Dr. Yang is committed to developing advanced cellular immunotherapeutics for aggressive cancers, especially for which with few effective therapies. By leveraging his expertise both in academia and industry, he significantly facilitates translational research and commercialization of the developed products. He is a pioneer of establishing a fully-automatic CAR-T cell manufacturing facility with the world’s cutting-edge platform in China. Hi is currently leading PersonGen to develop various first-in-class CAR-T cell therapeutics for treating hematologic malignancies and solid tumors.

正序生物专注于以自主知识产权的新型碱基编辑系统为基础，开发突破性精准基因编辑疗法。牟晓盾博士获美国伦斯勒理工大学化学生物学博士学位，复旦大学学士学位。拥有近20年的国际工业界经验，曾带领团队建立生物药的工艺开发、生产和全球IND/BLA申报平台，覆盖mAb，ADC，pDNA，viral vectors，mRNA，VLP等多种药物分子。在肿瘤免疫和感染性疾病治疗领域有深入CMC研发和生产质控经验。在基因和细胞治疗和罕见病领域亦有快速临床推进的经验。曾在药明生物担任副总裁和分公司负责人、在默沙东（美国）和辉瑞（美国）担任项目和研发团队负责人。
CorrectSequence Therapeutics aims to use independent development innovative gene editing system to help people living with serious diseases. Dr. Susan Mou received a doctorate degree in Chemical Biology from Rensselaer Polytechnic Institute, Troy NY, U.S.A. and bachelor’s degree in Chemistry from Fudan University. She has nearly 20 years industrial experience in CMC development and commercial manufacturing, quality, supply chain and new business establishment starting from 0 to 600 pl. Experienced in mAb, ADC, mRNA, VLP, AdV, AAV in therapeutic and preventive treatment, vaccine, CGT, rare disease. Served as the Vice President in WuXi Biologics Development and Manufacturing and the Site Head of Hangzhou, China, the senior scientist and project lead in Pfizer’s BioTherapeutics division (US) and the principal scientist and analytical leader of new and enabling technologies and CMC leader for BioProcess Development in Merck (MSD US).

孙艳
上海细胞治疗集团公司共同创始人，集团COO，上海细胞治疗集团药物技术有限公司总裁
带领团队基于“非病毒载体基因写入、纳米抗体及mRNA”一体化技术平台建设，致力于自分泌抗体差异化创新细胞药物开发。目前团队申请细胞治疗相关专利超270件，完成一系列高品质低成本的CAR-T细胞产品管线布局，其中BZ019为国内首个获批的基于非病毒载体的CAR-T细胞治疗药物；BZDS1901为国内首个自分泌PD-1纳米抗体的CAR-T细胞，率先在恶性间皮瘤上获得突破性的疗效初步验证。

刘雅容, 美国南加州大学博士、博士后，沙砾生物创始人、首席执行官，中山大学孙逸仙纪念医院逸仙医学客座教授；苏州工业园区科技领军人才、姑苏领军人才、上海“千人计划”专家，上海市浦江人才；正高级研究员，CSCO会员，女医师协会会员，浦东新区青年联合会委员；拥有10余年从事腺病毒、慢病毒等各种病毒载体用于定向基因治疗的研究经验，以及慢病毒产业化的经验；在Nature Communications， Science Immunology，Gene Therapy，Molecular Therapy 等国际顶级杂志发表40多篇论文。并拥有1项美国技术专利，申请发明专利70余项，主持上海市生物医药科技支撑项目1项，参与国家重大专项新药创制CART专项，作为第二完成人获得2017年浦东新区科技进步奖创业团队三等奖；2021年获得上海市创业新秀、长三角女性创新创业大赛银奖。2019年创立沙砾生物，致力于创新细胞疗法TIL在实体瘤的研发和临床应用。沙砾生物已建立了三大核心技术平台，多个管线在中美布局，其中GT101已进入临床I期实验中，是国内首个获批临床的TIL产品。
Yarong Liu, Ph.D. and Postdoctoral at University of Southern California, Founder and CEO at Grit Therapeutics, Visiting Professor at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Science and Technology Leader of Suzhou Industrial Park, Gusu Leader, Expert of Shanghai Thousand Talents Program, Shanghai Pujiang Talent, Principal Investigator, member of CSCO, member of China Medical Women's Association, and member of Pudong New Area Youth Federation. Over 10 years of experience in AAV, LVV and other viral vectors for targeted gene therapy and experience in LVV industrial-grade manufacturing. She has published more than 40 papers in top international journals such as Nature Communications, Science Immunology, Gene Therapy, and Molecular Therapy. She holds one U.S. technology patent and more than 70 invention patent applications. She is in charge of a biompharmaceutical science and technology support project of Shanghai, and participates in the national major new drug development project CART. She won the third prize of Pudong New Area Science and Technology Progress Award for startup team in 2017 as the second person-in-charge, and Shanghai New Entrepreneur award and silver award of Yangtze River Delta Women's Innovation and Startup Competition in 2021. In 2019, she founded Grit Therapeutics, which is dedicated to R&D and clinical application of innovative cell therapy TIL targeting solid tumors. Grit Therapeutics has developed three core technology platforms and multiple pipelines in China and the US, among which GT101, the first TIL with IND approval in China, has entered clinical phase I.

Graduated from National University of Singapore (NUS), Dr. Cecilia Zhang has been engaged in the R&D and translational research of cancer immunotherapy. As Chief Science Officer of Biosyngen, a Singapore-based biomedical company, Dr. Zhang is now leading a team to develop several next generation CAR-T, TCR-T and universal cell therapy pipelines to target unconquered cancer types, including nasopharyngeal carcinoma, gastric cancer, colorectal cancer, EB (Epstein-Barr) virus-positive lymphoma, etc.,. Dr. Zhang is also the owner of multiple renowned academic paper publications and invention patents of the field.
Currently, multiple investigator-initiated clinical trials of CAR-T and TCR-T therapies targeting EB virus are underway in multiple clinical centers in China and abroad, for which good safety profile and preliminary efficacy have been observed. Home to scientific research talents from Singapore, China, Germany, Australia, and French, Biosyngen and Dr. Zhang are committed to provide next-level cancer cure utilizing cutting-edge cell therapies to benefit cancer patients worldwide.

Dr. Zhang Yu is the CEO of VCANPHARMA, and the CSO&SVP of VCANBIO Cell&Gene Engineering Corp.,Ltd (600645, SH)
Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University (former name Beijing University of Aeronautics and Astronautics), and Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf in Germany. Dr. Zhang was the former president and CEO of Aeon Therapeutics Inc. (now part of JW Therapeutics (02126, HK)), which focused on developing First-in-class CAR-T products for solid tumors in China. He was a visiting scholar in University of Applied Sciences Bonn-Rhein-Sieg, German Aerospace Center and University of Palermo. Dr. Zhang is also a distinguished professor in School of Basic Medical Sciences, Tianjin Medical University; and a Principal Investigator of the State Industrial Base for Stem Cell Engineering Products (SIBSCEP). He acts as the director of Tianjin Key Laboratory of Stem Cell and Regenerative Medicine, the director of Tianjin Key Laboratory of Blood Cell Therapy Technology. Dr. Zhang is a member of ISSCR, ISCT, German Society of Stem Cell, and Chinese Society of Cell Biology. He has published a number of papers in high-profile journals, including eClinicalMedicine, eBioMedicine, STTT and Scientific Reports, as either first or corresponding author. He has been granted several patents. He is also a reviewer of several cell therapy journals, e.g. Stem Cell Research&Therapy. Dr. Zhang was the winner of “Tianjin 131 talent plan in Tianjin” and “Wuhan 3551 talent plan”.

陆金华博士是TriArm Therapeutic Co.的联合创始人，首席科学家。此前他在美国食品和药物管理局，作为临床前专家审评员，负责审评细胞和基因治疗，医疗器械，以及组合产品。他专长的领域是免疫治疗，基因/干细胞治疗和治疗性疫苗。在审评工作之外，他还任职多个科学委员会和工作小组，参与撰写FDA指导文件等工作。他曾担任美国FDA癌症卓越中心科学委员会成员，并获得FDA监管科学卓越成就奖。在任职FDA之前，他作为资深科学家，部门主管和咨询顾问服务于政府和生物技术工业界，负责研发用于肿瘤治疗的病毒载体和病毒疫苗。
Dr Lu is the co-founder and CSO of TriArm Therapeutic Co. He was an expert nonclinical reviewer at OTAT, CBER, FDA and specializes in reviewing immunotherapies, stem cell and gene therapies, and therapeutic cancer vaccines. He has regulatory experience in all stages of clinical development, from the Interact stage to BLA. He also served on numerous scientific committees and working groups, and participated in other FDA outreach activities with the biotech industry. Dr. Lu served as a member of scientific committee of Oncology Center of Excellence, FDA and was the recipient of the CBER award for Excellence in Regulatory Science Research in 2015.
Prior to joining the FDA, Dr Lu worked in the biotechnology industry as a senior scientist, manager and consultant in the development of vaccines for viral diseases and developing viral vectors for cancer therapy.

Jimin Gao, M.D., Ph.D.
Leading Talent in Zhejiang Province, Qianjiang-endowed Professor, Director of Zhejiang Provincial Key Laboratory for Technology and Application of Model Organisms, Wenzhou Medical University
Dr. Gao is a Leading Talent in Zhejiang Province and Qianjiang-endowed Professor. His research interests are the pathogenesis, immunological diagnosis and treatment of inflammation-related diseases (such as tumors). He has undertaken 8 national scientific research projects, published 146 SCI papers with 88 of them as the (co-)corresponding author, applied for 28 patents of invention with 6 of them authorized, won the first prize of Zhejiang Science and Technology Award in 2013 with the project “Cell surface-modified tumor cell vaccine”, and obtained a national new drug certificate (98 WeiYaoZhengZi S-09) for Injectable Recombinant Human G-CSF in 1998 with the profit tax of more than ￥100 million. Currently, his team has focused on the development of armored CAR-T, HLA-independent TCR-T, CAR-NK cells and cell-surface-modified tumor vaccines for safe and effective therapy of cancer, infection and aging.

近20年从业经验
韩国延世大学博士
哈佛医学院博士后
无锡市“锡山英才”创业领军人才
中国基因与细胞治疗CGCT“青藜学士”
王海峰博士于2022年1月创立无锡科金生物并担任董事长兼首席执行官。创立公司之前，王海峰博士曾在诺华（中国）从事研究工作，负责病毒方向的研究，并在核心期刊发表论文；之后在药明康德（韩国）从事亚太地区市场开发工作。主要负责抗体药、细胞和基因疗法的CDMO市场开发，参与近300多个国际项目，为亚太地区客户提供一站式技术服务，包括研发、CMC、Tox、IND和临床服务等，并帮助数十家公司从研发到IND直至BLA的成功提交。
20+ years of experience
PhD from Yonsei University, Korea,
Postdoc at Harvard Medical school,
Innovation and Entrepreneurship Leading Talents award of Wuxi’s Xishan Talents Program
"Bachelor of Chenopodium Album" award from China Gene & Cell Therapy (CGCT)
Dr. Michael Wang is the founder, Chairman and Chief Executive Officer of CorrGene Biotechnology Co., Ltd since the company’s founding in January 2022. Prior to founding CorrGene, Dr. Michael Wang was a research investigator of virology in Novartis (China). During his tenure at Novartis, Dr. Wang published several papers in key SCI-cited journals. After Novartis, Dr. Wang worked for WuXi AppTec (Korea) and responsible for business development in the Asia-Pacific region. When he served for Wuxi AppTec, his main responsibility was developing CDMO business and marketing of antibody drugs, gene and cell therapy related services, participating in nearly 300 international projects, providing one-stop technical services for customers in the Asia-Pacific region, including R&D, CMC, Tox, IND and clinical services, etc. During his tenure at WuXi AppTec, Dr. Wang successfully provided regulatory supports, ranging from IND submission to BLA approval, to dozens of companies.

Dr. Jun Li is the Chief Executive Officer and Founder of Fundamenta Therapeutics. Prior to founding Fundamenta, Dr. Li was a senior director at Novartis （2001-2009），leading multiple projects from discovery to IND. At Fundamenta Therapeutics, Dr. Li has led the development of a novel non-gene-editing allogeneic CAR-T platform technology (ThisCART) with the first program into clinical stage at multiple centers.
He obtained his bachelor’s degree in virology and molecular biology from Wuhan University in June 1992. He obtained his master’s degree in medical immunology from Peking University in June 1995 and Doctor’s degree in biochemistry from University of Utah in 2001. Dr. Li has published over 30 original papers in SCI-cited journals and authored in 26 international patents.

CSCO肿瘤生物标志物（bio-marker）专家委员会委员
CSCO肿瘤免疫（IO）治疗专家委员会委员
CAC肿瘤药物研究专业委员会荣誉委员
中国医药教育协会转化医学专业委员会常务委员
江苏省药学会药物临床评价研究专业委员会委员
临床与基础研究经历：
陆军军医大学博士，从事肿瘤临床工作14年。复旦大学博士后，从事肺癌水通道蛋白RNA干扰基础研究。
制药企业经历：
1. 三维生物，高级研究员，从事溶瘤病毒研发，2005年全球第一个溶瘤病毒（安柯瑞）获得NMPA批准的主要贡献者。
2. 辉瑞中国，医学事务部总监，负责肿瘤新产品的上市前和上市工作。
3. BMS，医学事务部肿瘤邻域负责人，高级总监，负责PD-1抑制剂（纳武利尤单抗）中国上市前和上市工作。
4. 武田中国 医学事务部负责人，副总裁

Dr. Alex H. Chang, is currently the Adjuct Professor of Tongji University School of Medicine and the founder of Shanghai YaKe Biotechnology Ltd.. He obtained his Ph.D. from University of British Columbia, Canada, and completed his post-doctoral training in Cell Engineering and Gene Therapy at Weill Medical College of Cornell University, New York. He has worked at Memorial Sloan-Kettering Cancer Centre, New York, as a senior scientist. During that period, he has several publications in cell engineering and gene therapy in renowned journals such as Nature Biotechnology, Nature Medicine, and Molecular Therapy.

Dr. Changfeng Zhang is the director of the Department of Regulatory Affairs, Shanghai Pharmaceuticals Holding Co., Ltd. He was one of the core members of Dr. Carl June’s team at the University of Pennsylvania and contributed substantially to the IND affairs of CTL019 (AKA Kymriah). Dr. Zhang specialized in RA affairs of CART products and achieved the IND approval of the first gene-modified CART product in China. Additionally, he established collaborations with the Chinese FDA, NICPBP, and several regulatory agencies by introducing world-famous CART therapists such as Drs. Stephan Grupp and Joseph Melenhorst. Dr. Zhang has several publications in top-ranked journals such as Nature Medicine, Blood, etc. He is also the High-level Talent of Shenzhen, Zhuhai, Suzhou, and Nanchang.

Dr. XIE got his Master’s degree in Medicine from Peking University and Ph.D in Pathogenic Biology from China CDC. He started his career as a scientist at the Peking University People’s Hospital, Peking University Hepatology Institute, and has devoted over 10 years to studying the genomics and immunobiology of cancer and their clinical implications. Dr. XIE is the founder, chairman and CEO of Corregene. He founded this cell therapy company in 2016, which focused on developing T-cell therapy for solid tumor patients.

Dr. Enxiu Wang used to work in Dr. Carl June team at University of Pennsylvania, the global pioneer of CAR-T immunothery. As a key member, he had been focused on solid tumor CAR design and evaluation. Dr. Wang and his colleges’ patents solft-activating CAR system has been approvaled by both US and European countries. He founded Nanjing CART medical Co. Ltd at 2017. Since then 3 patents have been approvaled and 35 submitted for solid tumor CAR-T. Recoginized by the field, Dr. Wang’s team obtained several fundings from the state and provinces. What’s more Nanjing CART got investment of noted investment institutions. Now leading with Dr. Wang, Nanjing CART Med is making great progress in both drug discovery and IND application.

• Base Therapeutics 创始人
• 在美国和中国的医疗领域具有近20年风险投资、创业、研发和临床医生的经验
• 仁济医院临床医生，Texas Children Hospital 临床遗传家，GE Healthcare主任科学家，应用干细胞公司首席科学家。主要科研成果包括世界上第一个发现了一种重要的遗传性心脏病ARVC的最主要的致病基因PKP2。
• 美国贝勒医学院（Baylor College of Medicine） 分子和人类遗传博士， 复旦大学临床医学七年制。

Life member of Chinese Society of Immunology, director of Immunology Committee of Hubei Cancer Society. Engaged in tumor immunotherapy research for nearly 20 years, involving preclinical and clinical studies of multiple Class I new drug projects. Presided over a number of major national science and technology projects such as "Major New Drug Development". He has applied for or obtained more than 20 national invention patents, obtained eight software copyrights, and published a monograph. Selected as the 2019 Leading Entrepreneur Talent Project in Suzhou Industrial Park. Entrepreneurship projects have won awards in multiple entrepreneurial competitions.

John Ng joined DHC in 2023 as General Manager of Asia Pacific, responsible for growing and supporting the Asia-Pacific market.
Before joining DHC, John served as CTO of Tessa Therapeutics. Tessa Therapeutics is a clinical-stage biotechnology company based in Singapore that is developing a portfolio of autologous and allogeneic cell therapy assets.
John joined Tessa Therapeutics as a member of its executive leadership team in 2016 and grew the company from 30 people to more than 200 people. He led the design, build, and validation of their multi-product integrated commercial cGMP facility (134,000 sq ft). The facility obtained the GMP certificate from the Health Authority of Singapore (HSA) to manufacture cell therapy products in early 2023.
As the CTO, John was responsible for the Operations organization, which includes Manufacturing, Process Development, Quality, Program Management, Engineering, and Global Supply Chain. Under his leadership, Tessa Therapeutics completed a phase 3 pivotal autologous cell therapy trial supplied by in-house manufacturing. He also led the translation of multiple programs with Tessa’s academic partners, executing successful tech transfers and comparability runs.
Before Tessa Therapeutics, John served in various leadership roles in Technical Operations in publicly listed companies. He spent ten years in China, responsible for Procurement, Global Supply Chain, and Program management.

Patrick Liu, MD, PhD is currently President at CureGenentics. Before joining CureGenetics, Dr. Liu had served as Chief Scientific Officer at Livzon Medicine Groups, Corporate Vice President and Chief Strategy Officer at Jiangsu Hengrui Medicine Groups, Vice President of Global Biologics at Teva Pharmaceuticals, R&D Director at Genentech, Inc. and Adjunct Professor at the University of Maryland.
Dr. Liu has more than 20 years of R&D strategies and management in innovative therapy development with increased responsibilities in the leadership role for the development and commercialization of a variety of new biologics and as well as cell and gene therapeutics products across the therapeutic areas of oncology, hematology, immunology, allergy, respiratory and infectious diseases. He has contributed to the success of developing many blockbuster innovative medicines including Avastin, Herceptin, Perjeta, Lucentis, Xolair and Copaxone, and many other biologics such as Lonquex, Granix, Ovaleap, Cinqair, Trogarzo and Ajovy. Dr Liu had practiced medicine, specializing in Endocrinology and also holds a Ph.D. in Molecular Biology and Biochemistry from Peking Union Medical College and Chinese Academy of Medical Sciences.

Fangfang Zhu, Founder and CEO of HemaCell Therapeutics Inc.
The tenure-track Associate Professor at Shanghai Jiao Tong University.
Dr. Zhu has over 15 years of experience in stem cell research and investment, she is the co-authors of many research articles published in high profile international journals, such as Cell Stem Cell, Nature Communication, PNAS, Nucleic Acids Research, et al, which have a total of nearly 2000 citations, and she is the inventors to several PCT patents, some of which have been licensed to biotech companies and research institute. Dr. Zhu was the Vice President of WI Harper Group, focusing on the early-stage investment at Healthcare field. Dr. Zhu was the Siebel Scholar at Stanford University and won the SVIEF “Sandhill” Investment Award. She was the former President and Chairman of PKU Alumni Association of Northern California (PKUAANC) and Secretary and Board Member of Zhejiang Chamber of Commerce, USA (ZCC-USA).
Dr. Zhu got her Ph.D. degree at cell biology from Peking University with the mentor Dr. Hongkui Deng and had her postdoctoral training in the Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, and her supervisor is Dr. Irving Weissman, the “Father of Stem Cells”.

Dr. Ting Zhang, founder and CEO of Regend Therapeutics, professor level senior engineer, doctor of biology of Tsinghua University, Shanghai "Pujiang Talent", innovation leader of Suzhou Industrial Park, Zhejiang "Qianjiang Talent", executive director of the base of the Tissue and Organ Regeneration and Manufacturing Engineering Research Center of the Ministry of Education, vice chairman of the Entrepreneur Federation of Nanchang National high-tech Zone Industry and Commerce Federation, Jiangxi Province, Vice President of East China Association of Entrepreneurs of Sichuan University Global Alumni Association, Entrepreneurship Tutor of Xi'an Jiaotong Liverpool University, and Member of the Alumni Association of Yihong Business School of Shenyang Pharmaceutical University. He used to be a postdoctoral researcher of the Genome Research Institute of A*STAR, Singapore, a postdoctoral researcher of UCSD and Sanford-Burnham Medical Research Institute in the United States, published 16 SCI papers on Nature, AJRCCM, EMBO Mol Med, Protein Cell, etc., three invention patents, served as the backbone of two national key research and development programs on stem cell and transformation research topics, won the second prize of Jiangsu Provincial Science and Technology Progress Award, and the 2022 Chinese Women Pioneer in Science and Technology.

Dr. Zhu received his Ph.D. in neurobiology from Shanghai Institute of Physiology, Chinese Academy of Sciences; conducted postdoctoral training at University of California San Francisco and Smith-Kettlewell Eye Research Institute. He is a recipient of the Rachel C. Atkinson Fellowship and Jiangsu Province Entrepreneurship and Innovation Talent. With experience in biopharmaceutical R&D and management both in the United States and China, he was the VP and CMO of Wanbang PharmaTech (A member of Fosun Pharma), and the EVP and CMO of Voncolytic Therapeutics.
朱博士从中科院上海生理所获得神经生物学博士，在加州大学旧金山分校和Smith-Kettlewell眼科研究所接受博士后训练；是Rachel C. Atkinson Fellowship和江苏省双创人才获得者；拥有美国和中国两国生物制药研发及管理经验，曾任万邦医药科技有限公司（复星医药）副总经理兼首席医学官、万戎生物医药科技有限公司常务副总经理兼首席医学官。

Biao Dong, Ph.D., is the co-founder and CEO of Sichuan Real&Best Biotech Co. Ltd. He is a Professor in the State Key Laboratory of Biotherapy and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University. His research interests include: (1) rAAV gene therapy of genetic diseases and age-related diseases; (2) rAAV production technology. He served as a member of ASGCT Viral Gene Transfer Vectors Committee and ASGCT Physical Delivery, Therapeutics & Vector Development Committee. Two rAAV gene therapy programs on Hemophilia A and B he led have been in the clinical study phase.

免疫学博士，浙江大学教授、博导。长期致力于胞外囊泡与免疫的研究。以通讯作者在Immunity, Journal of Extracellular Vesicles, Nature Communications, Cell Research, Autophagy等知名期刊发表SCI论文25篇。主持国家自然科学基金6项，包括重点项目1项；主持国家重点研究计划子课题1项，“973”计划骨干1项；以第一发明人获国家发明专利授权7项，申请2项；参编专著2部。目前任中国研究型医学学会细胞外囊泡研究与应用专业委员会常委、Extracell Vesicles Circ Nucl Acids杂志编委。应邀为Advanced Science, Theranostics，Cellular & Molecular Immunology等期刊审稿。

Shi Hu is an Associate Professor of Biomedical Engineering in the Department of Biophysics, Second Military Medical University, China. Professor Hu’s research is focused on synthetic immunology and antibody engineering through the development of novel immune therapeutics. In the last decade, he has focused on the development of novel sensitizers for antibody-based therapies (e.g., anti-ERBB antibodies) that underlie the mechanism research of tumor heterogeneity and plasticity. He has authored over 40 scientific publications in peer-reviewed journals and additional reviews and chapters in books on the molecular, biochemical, and cellular aspects of synthetic immunology and antibody engineering.

尹航，清华大学校学术委员会委员、校科技伦理委员会委员、药学院教授、原副院长。尹航教授现任Bioorganic & Medicinal Chemistry Letters主编、Journal of Extracellular Vesicle责任主编、Cell Chemical Biology编委、国际细胞外囊泡协会资深顾问、中国细胞外囊泡学会顾问、中国生物医药产业链创新与转化联盟重大需求与智库专委会主任委员、全国中药标准化技术委员会委员、中国药学会药物化学专委会委员。尹航教授团队在本领域一流期刊发表研究论文超过150篇(引用超2.5万次, H-Index>65)；科研成果已申请专利20余项（授予中国、美国、欧盟、日本等专利十余项），首创的1.1类候选药物获得美国FDA和中国CDE临床试验IND批准。尹航教授先后获得中组部国家特聘专家及中国科协海智特聘专家称号、国家自然基金委杰出青年科学基金、北京市卓越青年科学家奖、吴阶平-保罗·杨森医学药学奖、中国药学会科学技术一等奖、教育部自然科学二等奖、美国化学学会大卫·罗伯特森杰出药物化学家奖、美国癌症研究学会格特魯德·埃利恩奖、霍华德·休斯医学研究院合作创新奖、以及美国国家卫生研究院的 NIDA 青年化学家奖等多个奖项。

主任医师、教授、博士研究生导师
北京大学医学部本科、直博；德国海德堡大学访问学者；
中国医师奖、首都十大健康卫士 ；
入选北京市科技新星计划、北京市医管中心登峰计划、北京市百千万人才工程、教育部新世纪优秀人才；
现任美国视网膜专家协会会员、美国细胞外囊泡协会会员、亚太玻璃体视网膜协会会员、中国医师协会眼科医师分会葡萄膜炎与免疫专业委员会副主任委员、中华医学会眼科分会眼免疫学组委员；
担任Cell子刊《Cell Biomaterials》、《The Asia-Pacific Journal of Ophthalmology》、《中华眼底病杂志》等多家杂志编委。
已在NEJM、Nature Biomedical Engineering、Cell Reports Medicine、Ophthalmology等杂志发表SCI论文120篇。
眼内液检测技术为首都医科大学附属北京朝阳医院科创中心转化的第一个项目，已在全国24个省的1100余家医院得以应用，赋能3000名医生，帮助近10万疑难眼病患者寻找病因。

张灏，暨南大学医学院教授、博士生导师、博士后指导教授、肿瘤精准医学和病理研究所所长、教育部肿瘤分子生物学重点实验室副主任。主要研究方向包括1）RNA异常剪接及其蛋白产物在突变非依赖性肿瘤的驱动机制；2）抑癌基因酪氨酸磷酸酶在肿瘤中的调控机制和治疗靶点。以此为基础开展了转化研究包括：外泌体液体活检和免疫治疗，包括无创性唾液外泌体检测、基于嵌合RNA的外泌体疫苗、工程化外泌体包裹的抗体导向RNA药物等。获批多项发明专利，荣获《广东省科技进步奖二等奖》、《广东省医学科技奖二等奖》、《河南省科技进步一等奖》、《中国产学研合作创新奖》、《金博奖全球高层人才科技创新大赛金奖》、《全国十佳消化道领域临床研究金奖》、《中国研究型医院学会医学研究创新奖一等奖》、《中华医学科技奖三等奖》等。担任中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会（CSEMV）主委，《外泌体研究转化和临床应用专家共识》专家组组长，多个杂志的主编及编委。主编《肿瘤急诊病例治疗例析》，参编《Chimeric RNA》、《细胞外囊泡》、《Extracellular Vesicles: from bench to besides》等。

龙钢博士，复旦大学基础医学院病原生物系教授，博导。中科院“百人计划”专家。曾任中国科学院上海巴斯德研究所研究员, 清华大学结构生物学高精尖创新中心合作研究员。2002年中科院武汉病毒所毕业获得硕士学位；之后加入病毒所与荷兰瓦赫宁根大学病毒系联合培养博士项目，2007年获得博士学位;同年获得玛丽居里博士后奖学金支持加入德国海德堡大学医学院 Ralf Bartenschlager 教授团队从事丙肝病毒和登革热病毒分子病毒学研究。主持,参与十二五艾滋病肝炎研究重大专项、国家重点研发丙肝项目（973），生物安全项目和自然科学基金委项目,上海市重大项目等。研究方向为医学病毒的感染和致病机制及嗜神经病毒感染活细胞示踪体系研发。近年来龙钢研究员主要关注病毒组装与宿主相互作用，聚焦病毒组装与脂蛋白颗粒和外泌体颗粒交叉界面，提出外泌体和脂蛋白参与调控病毒感染和免疫逃逸的新模式，相关研究结果在J Hepatology，Nature Communications, Journal of Extracellular Vesicles, J Virol， AntiViral Research等学生刊物上发表。

Prat helps the faculty and researchers at MD Anderson develop collaborative opportunities with pharmaceutical, biotech, diagnostics, imaging, laboratory medicine and other industry partners. Prior to joining MD Anderson, Ferran held a number of industry and academic positions, including vice president, oncology and women’s health at Alere Inc. vice president for licensing at Biosite Inc., management consultant at McKinsey & Co., engineer at Chromogenia-Units and researcher at the University of California – Los Angeles. Prat has a Ph.D. in organic chemistry from the University of California – Los Angeles and a J.D. from the University of San Diego School of Law.

Dr. Lili Wang is a research associate professor and a research director at the Gene Therapy Program at the University of Pennsylvania. She has been in the field AAV gene therapy for over 25 years with extensive experience in the development of in vivo gene therapy for rare genetic diseases, including vector design & vector optimization, preclinical vector production, in vivo gene therapy in small and large animal models. Several of the preclinical programs she led have advanced to phase I - III clinical trials. Over the past 8 years, she has expanded her research interest to in vivo genome editing with CRISPR/Cas9 and meganuclease and demonstrated efficacy of in vivo genome editing/gene targeting as novel treatment approaches for liver metabolic diseases in mouse models and nonhuman primates. In her talk, she will discuss her work on developing AAV gene therapy and in vivo genome editing to treat OTC deficiency, an urea cycle disorder.

Huimin Tao is a principal scientist in the analytical development department at Novartis gene therapy. She leads of AD Molecular biology team in the development, qualification, and QC transfer of high-throughput sequencing and ddPCR assays to characterize AAV drug products. She has more than 15 year’s industry experience in molecular biology assay development. She was part of team at Sequenom launched the first NGS-based NIPT test in 2011. She is a member of the British Pharmacopeia Advanced Therapy Medicinal Products Working Party. Huimin used to be an attending physician in the third hospital of Wuhan, China, specializing in Neurology before she went to U.S. She received her master's degree in Neurology from Wuhan University, China, and her master's degree in public health from the University of Virginia, United States.

Markus finished his PhD in 2008 in Molecular Cell Biology at the Max-Planck-Institute for Biochemistry in Munich. He subsequently joined McKinsey&Company as a consultant taking over international strategy and operations projects for clients within the Pharma, Biotech and High-Tech industry.
By the end of 2010 Markus joined Roche at the Biotech Centre in Penzberg. Since then he was holding positions as a Groupleader and Department Head in Bioprocess Development and Analytical Development & New Technologies before he took over the Lead for Roche’s efforts towards Technical Development for in vivo Gene Therapy.

Prof. Dr. Dr. Rolf G. Werner is Honorary Senator of University of Tübingen and Professor for Industrial Biotechnology. After his promotion at University Tübingen he spent more than three years in academia at Max Planck Institute for Molecular Genetics, Berlin, Germany and Massachusetts Institute for Technology, Cambridge, USA and has more than 35 years experiences in industry at Boehringer Ingelheim in top leading positions. He was responsible for the development and registration of the first, genetically engineered, protein therapeutic from mammalian cell culture: tissue plasminogen activator for myocardial infarction and stroke. More than 20 therapeutic proteins and monoclonal antibodies have been developed, manufactured and regulatory approved under his responsibility. He designed an operated the first 6x15.000 L mammalian cell culture plant in Europe, constructed in 18 months. Under his supervision, also processes for viral therapeutics and vaccines have been developed. He is consulting biopharmaceutical, viral therapeutic and vaccine companies in Europe and Asia in all aspects of research and production technologies as well as conceptual design of GMP biotech plants. His achievements are recognized by the Prize of the City of Vienna, Austria, for outstanding scientific work as well as from the Hangzhou Government, China, as Hangzhou Qian Jiang Distinguished Expert in Biotechnology. He is National Foreign Expert in China.